Candelaria Gomez-Manzano, M.D., F.A.A.N., F.A.A.A.S.

Peer-Reviewed Articles

1. Morad, G, Damania, A, Melendez, B, Singh, BB, Veguilla, FJ, Soto, RA, Hoballah, YM, Sahasrabhojane, P, Wong, M, Ahmed, M, Rico, R, Lewis, KN, Wani, K, Shamsutdinova, D, Lazcano Segura, RN, Ingram, D, Goethe, E, Day, A, Flores, I, McDaniel, L, Chelvanambi, M, Johnson, S, Dimitriou, F, Gupta, P, Oberai, S, Zal, MA, Doss, P, Jamal, MA, Hayase, E, Wathoo, C, Norberg, L, Jenkins, SL, Nass, S, Gumin, J, Long, L, Yang, J, Bradley, GR, Bekal, MP, Dono, A, Pichardo-Rojas, PS, Andrewes, S, Ballester, L, Losh, JS, Liang, J, Huo, L, Nielsen, D, Parker Kerrigan, BC, Brastianos, PK, Fowlkes, NW, Chang, C, Jenq, RR, Gomez-Manzano, C, Huse, J, Davies, MA, Lazar, A, Bhat, KP, Tandon, N, Esquenazi, Y, Peterson, CB, Puduvalli, VK, Lang Jr, FF, Johnston, CD, Bullman, S, Ajami, NJ, Ferguson, SD, Wargo, J. Microbial signals in primary and metastatic brain tumors. Nature medicine 31(11):3675-3688, 2025. e-Pub 2025. PMID: 41238915.
2. Wu X, Ledbetter D, Tsai J, Singh S, Gumin J, Fan X, Gillard A, Shin DH, Jiang H, Zhao B, Ingram D, Akdmeir K, Conley A, Lazar A, Raza S, North R, Tatsui C, Lang F, Wang W, Rhines L, Gomez-Manzano C, Fueyo J, Alvarez-Breckenridge AC. Oncolytic Adenoviral Infection of Chordoma Achieves Treatment Efficacy through Immunogenic Cell Death and Tumor Microenvironment Alteration. Cancer Research. e-Pub 2025.
3. Morad G, Damania A, Melendez B, Singh B, Veguilla F, Soto R, Hoballah Y, Sahasrabhojane P, Wong M, Rico R, Wani K, Segura RL, Ingram D, Chelvanambi M, Johnson S, Dimitriou F, Gupta P, Oberai S, Zal M, Doss P, Chang C, Jamal M, Hayase E, Wathoo C, Norberg L, Jenkins S, Nass S, Gumin J, Long L, Yang J, Bradley G, Bekal MP, Dono A, Pichardo-Rojas P, Ballester L, Losh J, Liang J, Nielsen D, Kerrigan BP, Brastianos P, Fowlkes N, Jenq R, Gomez-Manzano C, Huse J, Davies M, Lazar A, Bhat K, Tandon N, Esquenazi Y, Peterson C, Puduvalli V, Lang F, Bullman S, Ajami N, Ferguson S, Ahmed M, Day A, Shamsutdinova D, Lewis K, Johnston C, Goethe E, Huo L, McDaniel L, Flores I, Andrewes S. Microbial signals in primary and metastatic brain tumors. Nature Medicine. e-Pub 2025.
4. Labiano S, Marco-Sanz J, Ausejo-Mauleon I, Laspidea V, Hernandez-Osuna R, Garcia-Moure M, Nava D, Nuin S, Gonzalez-Huarriz M, Phoenix TN, Tamayo I, Zalacain M, Lacalle A, Marrodan L, Puigdelloses M, Hervas-Corpion I, Ochoa MC, Casares N, Becher OJ, Gomez-Manzano C, Fueyo J, Perez-Larraya JG, Patino-Garcia A, Alonso MM. Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas. Cell Rep Med 6(7):102204, 2025. e-Pub 2025. PMID: 40578365.
5. de la Nava D, Ausejo-Mauleon I, Laspidea V, Gonzalez-Huarriz M, Lacalle A, Casares N, Zalacain M, Marrodan L, García-Moure M, Ochoa MC, Tallon-Cobos AC, Hernandez-Osuna R, Marco-Sanz J, Dhandapani L, Hervás-Corpión I, Becher OJ, Nazarian J, Mueller S, Phoenix TN, van der Lugt J, Hernaez M, Guruceaga E, Koschmann C, Venneti S, Allen JE, Dun MD, Fueyo J, Gomez-Manzano C, Gállego Pérez-Larraya J, Patiño-García A, Labiano S, Alonso MM. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models. Neuro Oncol 26(8):1509-1525, 2024. e-Pub 2024. PMID: 38554031.
6. Shin DH, Jiang H, Gillard AG, Kim D, Fan X, Singh SK, Nguyen TT, Sohoni SS, Lopez-Rivas AR, Parthasarathy A, Ene CI, Gumin J, Lang FF, Alonso MM, Gomez-Manzano C, Fueyo J. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice. Mol Therapy 32(3):722-733, 2024. e-Pub 2024. PMID: 38311852.
7. Meléndez-Vázquez NM, Nguyen TT, Fan X, López-Rivas AR, Fueyo J, Gomez-Manzano C, Godoy-Vitorino F. Gut microbiota composition is associated with the efficacy of Delta-24-RGDOX in malignant gliomas. Mol Ther Oncol 32(1):200787, 2024. e-Pub 2024. PMID: 38596290.
8. Kan P, Srinivasan VM, Gumin J, Garcia R, Chen SR, Johnson JN, Collins DE, Chen MM, Ledbetter D, Huse J, Evan Luna ZA, Robledo A, Vasandani V, Rao A, Singh SK, Shpall EJ, Fueyo J, Gomez-Manzano C, Lang FF. Development of a Rabbit Human Glioblastoma Model for Testing of Endovascular Selective Intra-Arterial Infusion (ESIA) of Novel Stem Cell-Based Therapeutics. Neuro Oncol 26(1):127-136, 2024. e-Pub 2024. PMID: 37603323.
9. Jiang H, Shin DH, Yi Y, Fan X, Gumin J, He J, Gillard AG, Lang FF, Gomez-Manzano C, Fueyo J. Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity. Cancer Res Commun 3(6):1118-1131, 2023. e-Pub 2023. PMID: 37379361.
10. Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, Á L, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh G. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat Med 29(6):1370-1378, 2023. e-Pub 2023. PMID: 37188783.
11. Nguyen TT, Shin DH, Sohoni S, Singh SK, Rivera-Molina Y, Jiang H, Fan X, Gumin J, Lang FF, Alvarez-Breckenridge C, Godoy-Vitorino F, Zhu L, Zheng WJ, Zhai L, Ladomersky E, Lauing KL, Alonso MM, Wainwright DA, Gomez-Manzano C, Fueyo J. Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. J Immunother Cancer 10(7), 2022. e-Pub 2022. PMID: 35902132.
12. Gállego Pérez-Larraya J, Garcia-Moure M, Labiano S, Patiño-García A, Dobbs J, Gonzalez-Huarriz M, Zalacain M, Marrodan L, Martinez-Velez N, Puigdelloses M, Laspidea V, Astigarraga I, Lopez-Ibor B, Cruz O, Oscoz Lizarbe M, Hervas-Stubbs S, Alkorta-Aranburu G, Tamayo I, Tavira B, Hernandez-Alcoceba R, Jones C, Dharmadhikari G, Ruiz-Moreno C, Stunnenberg H, Hulleman E, van der Lugt J, MÁ I, Diez-Valle R, Esparragosa Vázquez I, Villalba M, de Andrea C, Núñez-Córdoba JM, Ewald B, Robbins J, Fueyo J, Gomez-Manzano C, Lang FF, Tejada S, Alonso MM. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma. N Engl J Med 386(26):2471-2481, 2022. e-Pub 2022. PMID: 35767439.
13. Laspidea V, Puigdelloses M, Labiano S, Marrodán L, Garcia-Moure M, Zalacain M, Gonzalez-Huarriz M, Martínez-Vélez N, Ausejo-Mauleon I, de la Nava D, Herrador-Cañete G, Marco-Sanz J, Guruceaga E, de Andrea CE, Villalba M, Becher O, Squatrito M, Matía V, Gállego Pérez-Larraya J, Patiño-García A, Gupta S, Gomez-Manzano C, Fueyo J, Alonso MM. Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas. JCI Insight 7(7), 2022. e-Pub 2022. PMID: 35393952.
14. Martinez-Velez N, Laspidea V, Zalacain M, Labiano S, García-Moure M, Puigdelloses M, Marrodan L, Gonzalez-Huarriz M, Herrador G, de la Nava D, Ausejo-Mauleon I, Fueyo J, Gomez-Manzano C, Patiño-García A, Alonso MM. Local treatment of a pediatric osteosarcoma model with a 4-1BBL armed oncolytic adenovirus results in an antitumor effect and leads to immune memory. Mol Cancer Ther 21(3):471-480, 2022. e-Pub 2022. PMID: 34965961.
15. Shimizu Y, Gumin J, Gao F, Hossain A, Shpall EJ, Kondo A, Parker Kerrigan BC, Yang J, Ledbetter D, Fueyo J, Gomez-Manzano C, Lang FF. Characterization of patient-derived bone marrow human mesenchymal stem cells as oncolytic virus carriers for the treatment of glioblastoma. J Neurosurg 136(3):1-11, 2022. e-Pub 2022. PMID: 34450587.
16. Phillips LM, Li S, Gumin J, Daou M, Ledbetter D, Yang J, Singh S, Parker Kerrigan BC, Hossain A, Yuan Y, Gomez-Manzano C, Fueyo J, Lang FF. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus. Neuro Oncol 23(11):1911-1921, 2021. e-Pub 2021. PMID: 34059921.
17. Puigdelloses M, Garcia-Moure M, Labiano S, Laspidea V, Gonzalez-Huarriz M, Zalacain M, Marrodan L, Martinez-Velez N, De la Nava D, Ausejo I, Hervás-Stubbs S, Herrador G, Chen Z, Hambardzumyan D, Patino Garcia A, Jiang H, Gomez-Manzano C, Fueyo J, Gállego Pérez-Larraya J, Alonso M. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models. J Immunother Cancer 9(7), 2021. e-Pub 2021. PMID: 34281988.
18. Garcia-Moure M, Gonzalez-Huarriz M, Labiano S, Guruceaga E, Bandres E, Zalacain M, Marrodan L, de Andrea C, Villalba M, Martinez-Velez N, Laspidea V, Puigdelloses M, Gallego Perez-Larraya J, Iñigo-Marco I, Stripecke R, Chan JA, Raabe EH, Kool M, Gomez-Manzano C, Fueyo J, Patiño-García A, Alonso MM. Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT/RT and CNS-PNET. Clin Cancer Res 27(6):1807-1820, 2021. e-Pub 2021. PMID: 33376098.
19. Srinivasan VM, Gumin J, Camstra KM, Collins DE, Chen MM, Shpall EJ, Parker Kerrigan BC, Johnson JN, Chen SR, Fueyo J, Gomez-Manzano C, Lang FF, Kan P. Endovascular Selective Intra-Arterial Infusion of Mesenchymal Stem Cells Loaded With Delta-24 in a Canine Model. Neurosurgery 88(1):E102-E113, 2020. e-Pub 2020. PMID: 33231254.
20. de la Rocha AMA, González-Huarriz M, Guruceaga E, Mihelson N, Tejada-Solís S, Díez-Valle R, Martínez-Vélez N, Fueyo J, Gomez-Manzano C, Alonso MM, Laterra J, López-Bertoni H. miR-425-5p, a SOX2 target, regulates the expression of FOXJ3 and RAB31 and promotes the survival of GSCs. Arch Clin Biomed Res 4(3):221-238, 2020. e-Pub 2020. PMID: 32905473.
21. Jiang H, Shin DH, Nguyen TT, Fueyo J, Fan X, Henry V, Carrillo CC, Yi Y, Alonso MM, Collier TL, Yuan Y, Lang FF, Gomez-Manzano C. Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas. Clin Cancer Res 25(22):6801-6814, 2019. e-Pub 2019. PMID: 31455679.
22. Martínez-Vélez N, Garcia-Moure M, Marigil M, González-Huarriz M, Puigdelloses M, Gallego Pérez-Larraya J, Zalacaín M, Marrodán L, Varela-Guruceaga M, Laspidea V, Aristu JJ, Ramos LI, Tejada-Solís S, Díez-Valle R, Jones C, Mackay A, Martínez-Climent JA, García-Barchino MJ, Raabe E, Monje M, Becher OJ, Junier MP, El-Habr EA, Chneiweiss H, Aldave G, Jiang H, Fueyo J, Patiño-García A, Gomez-Manzano C, Alonso MM. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat Commun 10(1):2235, 2019. e-Pub 2019. PMID: 31138805.
23. Rivera-Molina Y, Jiang H, Fueyo J, Nguyen T, Shin DH, Youssef G, Fan X, Gumin J, Alonso MM, Phadnis S, Lang FF, Gomez-Manzano C. GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory. Neurooncol Adv 1(1):vdz009, 2019. e-Pub 2019. PMID: 31608328.
24. Martinez-Velez N, Marigil M, García-Moure M, Gonzalez-Huarriz M, Aristu JJ, Ramos-García LI, Tejada S, Díez-Valle R, Patiño-García A, Becher OJ, Gomez-Manzano C, Fueyo J, Alonso MM. Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models. Acta Neuropathol Commun 7(1):64, 2019. e-Pub 2019. PMID: 31036068.
25. Tejada S, Alonso M, Patiño A, Fueyo J, Gomez-Manzano C, Diez-Valle R. Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients. Neurosurgery, 2018. e-Pub 2018. PMID: 29088386.
26. Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, Prabhu SS, Rao G, Fuller GN, Aldape KD, Gumin J, Vence LM, Wistuba I, Rodriguez-Canales J, Villalobos PA, Dirven CMF, Tejada S, Valle RD, Alonso MM, Ewald B, Peterkin JJ, Tufaro F, Fueyo J. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. J Clin Oncol 36(14):JCO2017758219, 2018. e-Pub 2018. PMID: 29432077.
27. Tejada S, Díez-Valle R, Domínguez PD, Patiño-García A, González-Huarriz M, Fueyo J, Gomez-Manzano C, Idoate MA, Peterkin J, Alonso MM. DNX-2401, an Oncolytic Virus, for the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Gliomas: A Case Report. Front Oncol 8:61, 2018. e-Pub 2018. PMID: 29594041.
28. Hossain MB, Shifat R, Li J, Luo X, Hess KR, Rivera-Molina Y, Puerta Martinez F, Jiang H, Lang FF, Hung MC, Fueyo J, Gomez-Manzano C. TIE2 associates with caveolae and regulates caveolin-1 to promote their nuclear translocation. Mol Cell Biol 37(21), 2017. e-Pub 2017. PMID: 28760776.
29. Moreno M, Pedrosa L, Paré L, Pineda E, Bejarano L, Martínez J, Balasubramaniyan V, Ezhilarasan R, Kallarackal N, Kim SH, Wang J, Audia A, Conroy S, Marin M, Ribalta T, Pujol T, Herreros A, Tortosa A, Mira H, Alonso MM, Gómez-Manzano C, Graus F, Sulman EP, Piao X, Nakano I, Prat A, Bhat KP, de la Iglesia N. GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma. Cell Rep 21(8):2183-2197, 2017. e-Pub 2017. PMID: 29166609.
30. Jiang H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, Bover L, Vence LM, Yuan Y, Lang FF, Toniatti C, Hossain MB, Fueyo J. Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination. Cancer Res 77(14):3894-3907, 2017. e-Pub 2017. PMID: 28566332.
31. Xipell E, Aragón T, Martínez-Velez N, Vera B, Idoate MA, Martínez-Irujo JJ, Garzón AG, Gonzalez-Huarriz M, Acanda AM, Jones C, Lang FF, Fueyo J, Gomez-Manzano C, Alonso MM. Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51. Neuro Oncol 18(8):1109-19, 2016. e-Pub 2016. PMID: 26951384.
32. Xipell E, Gonzalez-Huarriz M, Martinez de Irujo JJ, García-Garzón A, Lang FF, Jiang H, Fueyo J, Gomez-Manzano C, Alonso MM. Salinomycin induced ROS results in abortive autophagy and leads to regulated necrosis in glioblastoma. Oncotarget 7(21):30626-41, 2016. e-Pub 2016. PMID: 27121320.
33. Hossain MB, Shifat R, Johnson DG, Bedford MT, Gabrusiewicz KR, Cortes-Santiago N, Luo X, Lu Z, Ezhilarasan R, Sulman EP, Jiang H, Li SS, Lang FF, Tyler J, Hung MC, Fueyo J, Gomez-Manzano C. TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1. Science Advances 2(4):e1501290, 2016. e-Pub 2016. PMID: 27757426.
34. Cortes-Santiago N, Hossain MB, Gabrusiewicz K, Fan X, Gumin J, Marini FC, Alonso MM, Lang F, Yung WK, Fueyo J, Gomez-Manzano C. Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas. Oncotarget 7(13):16146-57, 2016. e-Pub 2016. PMID: 26910374.
35. Acanda de la Rocha AM, López-Bertoni H, Guruceaga E, González-Huarriz M, Martínez-Vélez N, Xipell E, Fueyo J, Gomez-Manzano C, Alonso MM. Analysis of SOX2-Regulated Transcriptome in Glioma Stem Cells. PLoS One 11(9):e0163155, 2016. e-Pub 2016. PMID: 27669421.
36. Klein SR, Jiang H, Hossain MB, Fan X, Gumin J, Dong A, Alonso MM, Gomez-Manzano C, Fueyo J. Critical role of autophagy in the processing of adenovirus capsid-incorporated cancer-specific antigens. PLoS One 11(4):e0153814, 2016. e-Pub 2016. PMID: 27093696.
37. Avci NG, Fan Y, Dragomir A, Akay YM, Gomez-Manzano C, Fueyo-Margareto J, Akay M. Delta-24-RGD Induces Cytotoxicity of Glioblastoma Spheroids in Three Dimensional PEG Microwells. IEEE Trans Nanobioscience 14(8):946-51, 2015. e-Pub 2015. PMID: 26661633.
38. Klein SR, Piya S, Lu Z, Xia Y, Alonso MM, White EJ, Wei J, Gomez-Manzano C, Jiang H, Fueyo J. C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy. Oncogene 34(41):5295-301, 2015. e-Pub 2015. PMID: 25619840.
39. Gabrusiewicz K, Hossain MB, Cortes-Santiago N, Fan X, Kaminska B, Marini FC, Fueyo J, Gomez-Manzano C. Macrophage Ablation Reduces M2-Like Populations and Jeopardizes Tumor Growth in a MAFIA-Based Glioma Model. Neoplasia 17(4):374-84, 2015. e-Pub 2015. PMID: 25925380.
40. Martinez-Velez N, Xipell E, Jauregui P, Zalacain M, Marrodan L, Zandueta C, Vera B, Urquiza L, Sierrasesúmaga L, Julián MS, Toledo G, Fueyo J, Gomez-Manzano C, Torre W, Lecanda F, Patiño-García A, Alonso MM. The Oncolytic Adenovirus Delta24-RGD in Combination with Cisplatin Exerts a Potent Anti-Osteosarcoma Activity. J Bone Miner Res 29(10):2287-96, 2014. e-Pub 2014. PMID: 24737304.
41. Gabrusiewicz K, Liu D, Cortes-Santiago N, Hossain MB, Conrad CA, Aldape KD, Fuller GN, Marini FC, Alonso MM, Idoate MA, Gilbert MR, Fueyo J, Gomez-Manzano C. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget 5(8):2208-20, 2014. e-Pub 2014. PMID: 24809734.
42. Jiang H, Clise-Dwyer K, Ruisaard KE, Fan X, Tian W, Gumin J, Lamfers ML, Kleijn A, Lang FF, Yung WK, Vence LM, Gomez-Manzano C, Fueyo J. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One 9(5):e97407, 2014. e-Pub 2014. PMID: 24827739.
43. Martín V, Sanchez-Sanchez AM, Herrera F, Gomez-Manzano C, Fueyo J, Alvarez-Vega MA, Antolín I, Rodriguez C. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br J Cancer 108(10):2005-12, 2013. e-Pub 2013. PMID: 23632480.
44. Jiang H, White EJ, Ríos-Vicil CI, Xu J, Gomez-Manzano C, Fueyo J. Human Adenovirus Type 5 Induces Cell Lysis through Autophagy and Autophagy-Triggered Caspase Activity. J Virol 85(10):4720-9, 2011. e-Pub 2011. PMID: 21367888.
45. Mohamedali KA, Ran S, Gomez-Manzano C, Ramdas L, Xu J, Kim S, Cheung LH, Hittelman WN, Zhang W, Waltenberger J, Thorpe PE, Rosenblum MG. Cytotoxicity of VEGF121/rGel on Vascular Endothelial Cells Resulting in Inhibition of Angiogenesis is Mediated via VEGFR-2. BMC Cancer 11:358, 2011. e-Pub 2011. PMID: 21849059.
46. Alonso MM, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N, Urquiza L, Jauregi P, de Munain AL, Sampron N, Aramburu A, Tejada-Solis S, Vicente C, Odero MD, Bandres E, Garcia-Foncillas J, Idoate MA, Lang FF, Fueyo J, Gomez-Manzano C. Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One 6(11):e26740, 2011. e-Pub 2011. PMID: 22069467.
47. Piya S, White EJ, Klein SR, Jiang H, McDonnell TJ, Gomez-Manzano C, Fueyo J. The E1B19K oncoprotein complexes with Beclin 1 to regulate autophagy in adenovirus-infected cells. PLoS One 6(12):e29467, 2011. e-Pub 2011. PMID: 22242123.
48. Liu D, Martin V, Fueyo J, Lee OH, Xu J, Cortes-Santiago N, Alonso MM, Aldape K, Colman H, Gomez-Manzano C. Tie2/TEK Modulates the Interaction of Glioma and Brain Tumor Stem Cells with Endothelial Cells and Promotes an Invasive Phenotype. Oncotarget 1(8):700-9, 2010. e-Pub 2010. PMID: 21321379.
49. Jiang H, Martin V, Gomez-Manzano C, Johnson DG, Alonso M, White E, Xu J, McDonnell TJ, Shinojima N, Fueyo J. The RB-E2F1 Pathway Regulates Autophagy. Cancer Res 70(20):7882-93, 2010. e-Pub 2010. PMID: 20807803.
50. Dembinski JL, Spaeth EL, Fueyo J, Gomez-Manzano C, Studeny M, Andreeff M, Marini FC. Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Cancer Gene Ther 17(4):289-297, 2010. e-Pub 2010. PMID: 19876078.
51. Martin V, Xu J, Pabbisetty SK, Alonso MM, Liu D, Lee OH, Gumin J, Bhat KP, Colman H, Lang FF, Fueyo J, Gomez-Manzano C. Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters. Oncogene 28(24):2358-63, 2009. e-Pub 2009. PMID: 19421150.
52. Piao Y, Jiang H, Alemany R, Krasnykn V, Marini FC, Xu J, Alonso MM, Conrad C, Aldape KD, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Ther 16(3):256-65, 2009. e-Pub 2009. PMID: 18927600.
53. Alonso MM, Jiang H, Yokoyama T, Xu J, Bekele NB, Lang FF, Kondo S, Gomez-Manzano C, Fueyo J. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther 16(3):487-93, 2008. e-Pub 2008. PMID: 18253154.
54. Lee OH, Xu J, Fueyo J, Alonso MM, Liu D, Martin V, Jiang H, Piao Y, Liu TJ, Gomez-Manzano C. Angiopoietin-2 decreases vascular endothelial growth factor expression by modulating HIF-1 alpha levels in gliomas. Oncogene 27(9):1310-1314, 2008. e-Pub 2008. PMID: 17704802.
55. Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad C, Aldape KD, deGroot JF, Bekele BN, Yung WK. VEGF trap induces antiglioma effect at different stages of disease. Neuro Oncol 10(6):940-5, 2008. e-Pub 2008. PMID: 18708344.
56. Alonso MM, Gomez-Manzano C, Bekele BN, Yung WK, Fueyo J. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res 67(24):11499-504, 2007. e-Pub 2007. PMID: 18089777.
57. Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F, Xu J, Kondo Y, Bekele BN, Colman H, Lang FF, Fueyo J. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst 99(18):1410-4, 2007. e-Pub 2007. PMID: 17848677.
58. Alonso MM, Cascallo M, Gomez-Manzano C, Jiang H, Bekele BN, Perez-Gimenez A, Lang FF, Piao Y, Alemany R, Fueyo J. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. Cancer Res 67(17):8255-63, 2007. e-Pub 2007. PMID: 17804740.
59. Alonso MM, Gomez-Manzano C, Jiang H, Bekele NB, Piao Y, Yung WK, Alemany R, Fueyo J. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther 14(8):756-761, 2007. e-Pub 2007. PMID: 17557108.
60. Olson MV, Johnson DG, Jiang H, Xu J, Alonso MM, Aldape KD, Fuller GN, Bekele BN, Yung WK, Gomez-Manzano C, Fueyo J. Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. Cancer Res 67(9):4005-4009, 2007. e-Pub 2007. PMID: 17483310.
61. Jiang H, Olson MV, Medrano DR, Lee OH, Xu J, Piao Y, Alonso MM, Gomez-Manzano C, Hung MC, Yung WK, Fueyo J. A novel CRM1-dependent nuclear export signal in adenoviral E1A protein regulated by phosphorylation. Faseb J 20:2603-5, 2006. e-Pub 2006. PMID: 17065226.
62. Lee OH, Xu J, Fueyo J, Fuller GN, Aldape KD, Alonso MM, Piao Y, Liu TJ, Lang FF, Bekele BN, Gomez-Manzano C. Expression of the receptor tyrosine kinase Tie2 in neoplastic glial cells is associated with integrin beta1-dependent adhesion to the extracellular matrix. Mol Cancer Res 4:915-26, 2006. e-Pub 2006. PMID: 17189382.
63. Lee OH, Fueyo J, Xu J, Yung WK, Lemoine MG, Lang FF, Bekele BN, Zhou X, Alonso MA, Aldape KD, Fuller GN, Gomez-Manzano C. Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. Neoplasia 8:419-28, 2006. e-Pub 2006. PMID: 16790091.
64. Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF, Jiang H, Bekele BN, Zhou X, Alemany R, Fueyo J. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res 12(2):556-62, 2006. e-Pub 2006. PMID: 16428500.
65. Alonso MM, Fueyo J, Shay JW, Aldape KD, Jiang H, Lee OH, Johnson DG, Xu J, Kondo Y, Kanzawa T, Kyo S, Bekele BN, Zhou X, Nigro J, McDonald JM, Yung WK, Gomez-Manzano C. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. J Natl Cancer Inst 97(21):1589-600, 2005. e-Pub 2005. PMID: 16264179.
66. Jiang H, Alemany R, Gomez-Manzano C, Medrano DR, Lemoine MG, Olson MV, Alonso MM, Lee OH, Conrad CC, Yung WK, Fueyo J. Downmodulation of E1A protein expression as a novel strategy to design cancer-selective adenoviruses. Neoplasia 7(8):723-9, 2005. e-Pub 2005. PMID: 16207474.
67. Conrad C, Miller CR, Ji Y, Gomez-Manzano C, Bharara S, McMurray JS, Lang FF, Wong F, Sawaya R, Yung WK, Fueyo J. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther 12(3):284-94, 2005. e-Pub 2005. PMID: 15650766.
68. Jiang H, Gomez-Manzano C, Alemany R, Medrano D, Alonso M, Bekele BN, Lin E, Conrad CC, Yung WK, Fueyo J. Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas. Neoplasia 7(1):48-56, 2005. e-Pub 2005. PMID: 15720816.
69. Stolarek R, Gomez-Manzano C, Jiang H, Suttle G, Lemoine MG, Fueyo J. Robust infectivity and replication of Delta-24 adenovirus induce cell death in human medulloblastoma. Cancer Gene Ther 11(11):713-20, 2004. e-Pub 2004. PMID: 15332115.
70. Gomez-Manzano C, Balague C, Alemany R, Lemoine MG, Mitlianga P, Jiang H, Khan A, Alonso M, Lang FF, Conrad CA, Liu TJ, Bekele BN, Yung WK, Fueyo J. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene 23(10):1821-8, 2004. e-Pub 2004. PMID: 15014451.
71. Lee HY, Srinivas H, Xia D, Lu Y, Superty R, LaPushin R, Gomez-Manzano C, Gal AM, Walsh GL, Force T, Ueki K, Mills GB, Kurie JM. Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival. J Biol Chem 278(26):23630-8, 2003. e-Pub 2003. PMID: 12714585.
72. Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, Sawaya R, Curiel DT, Yung WK, Lang FF. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 95(9):652-60, 2003. e-Pub 2003. PMID: 12734316.
73. Gomez-Manzano C, Fueyo J, Jiang H, Glass TL, Lee HY, Hu M, Liu JL, Jasti SL, Liu TJ, Conrad CA, Yung WK. Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis. Ann Neurol 53(1):109-17, 2003. e-Pub 2003. PMID: 12509854.
74. Mitlianga PG, Gomez-Manzano C, Kyritsis AP, Fueyo J. Overexpression of E2F-1 leads to bax-independent cell death in human glioma cells. Int J Oncol 21(5):1015-20, 2002. e-Pub 2002. PMID: 12370749.
75. Gomez-Manzano C, Mitlianga P, Fueyo J, Lee HY, Hu M, Spurgers KB, Glass TL, Koul D, Liu TJ, McDonnell TJ, Yung WK. Transfer of E2F-1 to human glioma cells results in transcriptional up-regulation of Bcl-2. Cancer Res 61(18):6693-7, 2001. e-Pub 2001. PMID: 11559537.
76. Gomez-Manzano C, Lemoine MG, Hu M, He J, Mitlianga P, Liu TJ, Yung AW, Fueyo J, Groves MD. Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. Int J Oncol 19(2):359-65, 2001. e-Pub 2001. PMID: 11445852.
77. Im SA, Kim JS, Gomez-Manzano C, Fueyo J, Liu TJ, Cho MS, Seong CM, Lee SN, Hong YK, Yung WK. Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF. Br J Cancer 84(9):1252-7, 2001. e-Pub 2001. PMID: 11336478.
78. Mitlianga PG, Kyritsis AP, Gomez-Manzano C, Lemoine MG, Hu M, Liu TJ, Yung WK, Fueyo J. Co-expression of E2F-2 enhances the p53 anti-cancer effect in human glioma cells. Int J Oncol 18(2):343-7, 2001. e-Pub 2001. PMID: 11172602.
79. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19(1):2-12, 2000. e-Pub 2000. PMID: 10644974.
80. Im SA, Gomez-Manzano C, Fueyo J, Liu TJ, Ke LD, Kim JS, Lee HY, Steck PA, Kyritsis AP, Yung WK. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 59(4):895-900, 1999. e-Pub 1999. PMID: 10029081.
81. Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, McDonnell TJ, Shi X, Rao JS, Levin VA, Kyritsis AP. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med 4(6):685-90, 1998. e-Pub 1998. PMID: 9623977.
82. Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, Bruner JM, Chintala SK, Rao JS, Levin VA, Kyritsis AP. Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology 50(5):1307-15, 1998. e-Pub 1998. PMID: 9595979.
83. Fueyo J, Gomez-Manzano C, Puduvalli VK, Martin-Duque P, Perez-Soler R, Levin VA, Yung WK, Kyritsis AP. Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy. Int J Oncol 12(3):665-9, 1998. e-Pub 1998. PMID: 9472109.
84. Chintala SK, Fueyo J, Gomez-Manzano C, Venkaiah B, Bjerkvig R, Yung WK, Sawaya R, Kyritsis AP, Rao JS. Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene 15(17):2049-57, 1997. e-Pub 1997. PMID: 9366522.
85. Gomez-Manzano C, Fueyo J, Kyritsis AP, McDonnell TJ, Steck PA, Levin VA, Yung WK. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst 89(14):1036-44, 1997. e-Pub 1997. PMID: 9230885.
86. Fueyo J, Gomez-Manzano C, Bruner JM, Saito Y, Zhang B, Zhang W, Levin VA, Yung WK, Kyritsis AP. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene 13(8):1615-9, 1996. e-Pub 1996. PMID: 8895506.
87. Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KD, Levin VA, Yung WK. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 56(4):694-9, 1996. e-Pub 1996. PMID: 8630997.
88. EAFT (European Atrial Fibrillation Trial) Study Group 1. Silent brain infarction in nonrheumatic atrial fibrillation. EAFT Study Group. European Atrial Fibrillation Trial. Neurology 46(1):159-65, 1996. e-Pub 1996. PMID: 8559367.
89. Fueyo J, Gomez-Manzano C, Yung WK, Clayman GL, Liu TJ, Bruner J, Levin VA, Kyritsis AP. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12(1):103-10, 1996. e-Pub 1996. PMID: 8552379.
90. Fueyo J, Gomez-Manzano C, Yung WK, Zhang W, Lee PS, Majumder S, Perhouse M, Levin VA, Kyritsis AP. A frequent polymorphism in exon 1 of the p16/CDKN2 gene. Mol Cell Probes 9(6):465-6, 1995. e-Pub 1995. PMID: 8808318.
91. Singer DE, Hylek EM, group AE. Optimal oral anticoagulation for patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 333(22):1504, 1995. e-Pub 1995. PMID: 7477157.
92. EAFT (European Atrial Fibrillation Trial) Study Group 1. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 342(8882):1255-62, 1993. e-Pub 1993. PMID: 7901582.
93. Pou A, Fueyo J, Gomez-Manzano C. Paraneoplastic encephalomyelitis and Lambert-Eaton syndrome. Revue Neurol (Paris) 148:605-609, 1992. e-Pub 1992.
94. Ene C, Dr Singh SK, Venkataraman T, Phillips LM, Long JP, Singh D, Tran ND, Tufaro F, Anand PJ, Navin NE, Prabhu S, Weinberg JS, Larman B, Gomez-Manzano C, Fueyo J, Lang FF. Systemic immune correlates of long-term survival after Delta-24-RGD based on the Therapeutic Adenovirus for Recurrent Glioblastoma Effect Trial (TARGET). Clin Cancer Res.
95. Meléndez-Vázquez NM, Van Wieren A, Sohoni S, Bolaños-Rosero B, Fueyo J, Gomez-Manzano C, Godoy-Vitorino F. Immune-microbe responses to viroimmunotherapy against gastric cancer: a dynamic multi-kingdom approach. Cancer Discover.
96. Gomez-Manzano C, Shin DH, Gillard A, Alvarez-Breckenridge C, Alonso M, Lang F, Fueyo J. Diverse Origin and Nature of Tumor-Infiltrating Lymphocytes: The Infection Hypothesis. Cancer Cell.

Invited Articles

1. Garcia-Moure M, Gillard AG, Alonso MM, Fueyo J, Gomez-Manzano C. Oncolytic adenoviruses and immunopeptidomics: a convenient marriage. Mol Oncol 18(4):781-784, 2024. e-Pub 2024. PMID: 38561242.
2. Vogelbaum MA, Li G, Heimberger AB, Lang FF, Fueyo J, Gomez-Manzano C, Sanai N. A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology. Am Soc Clin Oncol Educ Book (American Society of Clinical Oncology) 42:1-8, 2022. e-Pub 2022. PMID: 35580289.
3. Fueyo J, Gomez-Manzano C, Lang FF, Alonso MM. Hitchhiking to brain tumours: stem cell delivery of oncolytic viruses. Lancet Oncol 22(8):1049-1051, 2021. e-Pub 2021. PMID: 34214494.
4. Varela-Guruceaga M, Tejada-Solís S, García-Moure M, Fueyo J, Gomez-Manzano C, Patiño-García A, Alonso MM. Oncolytic Viruses as Therapeutic Tools for Pediatric Brain Tumors. Cancers (Basel) 10(7), 2018. e-Pub 2018. PMID: 29987215.
5. Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res 18(1):84, 2016. e-Pub 2016. PMID: 27515302.
6. Klionsky DJ, Gomez-Manzano C, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12(1):1-222, 2016. e-Pub 2016. PMID: 26799652.
7. Jiang H, Gomez-Manzano C, Rivera-Molina Y, Lang FF, Conrad CA, Fueyo J. Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints. Curr Opin Virol 13:33-39, 2015. e-Pub 2015. PMID: 25863716.
8. Hossain MB, Cortes-Santiago N, Liu D, Martin V, Gomez-Manzano C. TEK (TEK tyrosine kinase, endothelial). Atlas Genet Cytogenet Oncol Haematol 16(9):669-673, 2012. e-Pub 2012.
9. Klionsky DJ, Abdalla FC, Abeliovich H, Gomez-Manzano C, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8(4):445-544, 2012. e-Pub 2012. PMID: 22966490.
10. Balvers R, Jiang H, Piya S, Gomez-Manzano C, Fueyo J. Adenovirus, Autophagy, and Lysis: Ecstasies and Agonies. Future Virology 6(10):1161-1164, 2011. e-Pub 2011.
11. Fueyo J, Gomez-Manzano C, Yung WK. Advances in Translational Research in Neuro-Oncology. Arch Neurol 68(3):303-8, 2011. e-Pub 2011. PMID: 21059986.
12. White EJ, Martin V, Liu JL, Klein SR, Piya S, Gomez-Manzano C, Fueyo J, Jiang H. Autophagy regulation in cancer development and therapy. Am J Cancer Res 1(3):362-372, 2011. e-Pub 2011. PMID: 21969237.
13. Jiang H, Martin V, Alonso M, Gomez-Manzano C, Fueyo J. Rb-E2F1: Molecular rheostat for autophagy and apoptosis. Autophagy 6(8):1216-7, 2010. e-Pub 2010. PMID: 20935482.
14. Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses for the treatment of brain tumors. Curr Opin Mol Ther 12(5):530-7, 2010. e-Pub 2010. PMID: 20886384.
15. Jiang H, Gomez-Manzano C, Lang F, Alemany R, Fueyo J. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther 9(5):422-7, 2009. e-Pub 2009. PMID: 19860656.
16. Liu D, Martin V, Gomez-Manzano C. TEK (TEK tyrosine kinase, endothelial). Atlas Genet Cytogenet Oncol Haematol 13(12):975-977, 2009. e-Pub 2009.
17. Jiang H, White EJ, Conrad C, Gomez-Manzano C, Fueyo J. Autophagy pathways in glioblastoma. Methods in Enzymology 453(Autophagy in Disease and Clinical Applications):273-86, 2009. e-Pub 2009. PMID: 19216911.
18. Martin V, Liu D, Gomez-Manzano C. Encountering and advancing through antiangiogenesis therapy for gliomas. Curr Pharm Des 15(4):353-64, 2009. e-Pub 2009. PMID: 19199963.
19. Martin V, Liu D, Fueyo J, Gomez-Manzano C. Tie2: a journey from normal angiogenesis to cancer and beyond. Histol Histopathol 23(6):773-80, 2008. e-Pub 2008. PMID: 18366015.
20. Alonso MM, Alemany R, Fueyo J, Gomez-Manzano C. E2F1 in gliomas: A paradigm of oncogene addiction. Cancer Lett 263(2):157-63, 2008. e-Pub 2008. PMID: 18334281.
21. Gomez-Manzano C, Alonso M, Jiang H, Fueyo J. Interspecies adenovirus fiber shows "evolutionary" advantage for oncolytic therapy of gliomas. Cancer Biol Ther 11(7):794-6, 2008. e-Pub 2008. PMID: 18756625.
22. Jiang H, White EJ, Gomez-Manzano C, Fueyo J. Adenovirus's last trick: you say lysis, we say autophagy. Autophagy 4(1):118-20, 2008. e-Pub 2008. PMID: 18032923.
23. Jiang H, Alonso MM, Gomez-Manzano C, Piao Y, Fueyo J. Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas. Expert Rev Anticancer Ther 6:1585-92, 2006. e-Pub 2006. PMID: 17134363.
24. Jiang H, McCormick F, Lang FF, Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses as antiglioma agents. Expert Rev Anticancer Ther 6:697-708, 2006. e-Pub 2006. PMID: 16759161.
25. Alonso MM, Fueyo J, Yung WKA, Gomez-Manzano C. E2F1 and telomerase: alliance in the dark side. Cell Cycle 5(9):930-5, 2006. e-Pub 2006. PMID: 16628012.
26. Gomez-Manzano C, Yung WK, Alemany R, Fueyo J. Genetically modified adenoviruses against gliomas: from bench to bedside. Neurology 63(3):418-26, 2004. e-Pub 2004. PMID: 15304571.
27. Jiang H, Conrad C, Fueyo J, Gomez-Manzano C, Liu TJ. Oncolytic adenovirus for malignant glioma therapy. Frontiers in Bioscience 8:D577-88, 2003. e-Pub 2003.
28. Alemany R, Gomez-Manzano C, Fueyo J. [Oncolytic adenovirus for the treatment of cerebral tumors: past, present and future]. Neurologia 16(3):122-7, 2001. e-Pub 2001. PMID: 11333782.
29. Fueyo J, Gomez-Manzano C, Liu TJ, Yung WKA. Delivery of cell cycle genes to block astrocytoma growth. J Neuro-Oncol 51(3):277-87, 2001. e-Pub 2001. PMID: 11407598.
30. Alemany R, Gomez-Manzano C, Balague C, Yung WK, Curiel DT, Kyritsis AP, Fueyo J. Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res 252(1):1-12, 1999. e-Pub 1999. PMID: 10502394.
31. Fueyo J, Gomez-Manzano C, Yung WK, Kyritsis AP. Targeting in gene therapy for gliomas. Arch Neurol 56(4):445-8, 1999. e-Pub 1999. PMID: 10199333.
32. Gomez-Manzano C, Yung WKA. Gene therapy for gliomas. Biomedicina 2:242-244, 1999. e-Pub 1999.
33. Gomez-Manzano C, Fueyo J, Alameda F, Kyritsis AP, Yung WK. Gene therapy for gliomas: p53 and E2F-1 proteins and the target of apoptosis. Int J Mol Med 3(1):81-5, 1999. e-Pub 1999. PMID: 9864390.
34. Fueyo J, Gomez-Manzano C, Yung WK, Kyritsis AP. The functional role of tumor suppressor genes in gliomas: clues for future therapeutic strategies. Neurology 51(5):1250-5, 1998. e-Pub 1998. PMID: 9818841.
35. Fueyo J, Gomez-Manzano C. Molecular control of the cellular cycle and apoptosis: new treatments for gliomas. Neurologia 8:43-47, 1998. e-Pub 1998.
36. Illa I, Gallardo E, Gomez-Manzano C, Juarez-Rubio C. Inflammatory Myopathies: Histopathological and immunopathological features and treatment. Revista Espanola de Reumatolologia 20:293-298, 1993. e-Pub 1993.

Review Articles

1. Elgehiny, A, Fan, AE, Frost, M, He, J, Gary, S, Osorio, DS, Zaky, W, Zhou, L, Kang, K, Zhang, Z, Fueyo-Margareto, J, Gomez-Manzano, C, Thompson, EM, Bernstock, J, Friedman, GK. Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors. Journal of Neuro-Oncology 177(1), 2026. e-Pub 2026. PMID: 41741902.
2. Shin, DH, Alonso, MM, Gomez-Manzano, C, Fueyo-Margareto, J. Virus Against Cancer: Paradigm-Shifting Biological Concepts. Current neurology and neuroscience reports 25(1), 2025. e-Pub 2025. PMID: 40515944.
3. Parthasarathy A, Frost M, Gillard AG, Alonso MM, Gomez-Manzano C, Fueyo J. The multilayered control of acetylation during adenovirus-based immunotherapy of cancer. Mol Ther Oncol 33(2):200976, 2025. e-Pub 2025. PMID: 40236995.
4. Melendez-Vazquez NM, Gomez-Manzano C, Godoy-Vitorino F. Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas. Viruses 16(11), 2024. e-Pub 2024. PMID: 39599889.
5. He J, Connors J, Meador A, Xu S, Meador H, Jiang H, Fueyo J, Gomez-Manzano C, Friedman GK, Zaky W, Sadighi Z, Slopis JM, Ahmad AH. Immunotherapy-Related Neurotoxicity in the Central Nervous System of Children with Cancer. Neuro Oncol 27(3):625-643, 2024. e-Pub 2024. PMID: 39535217.
6. Garcia-Moure M, Laspidea V, Gupta S, Gillard AG, Khatua S, Parthasarathy A, He J, Lang FF, Fueyo J, Alonso MM, Gomez-Manzano C. The emerging field of viroimmunotherapy for pediatric brain tumors. [COVER ISSUE]. Neuro Oncol 26(11):1981-1993, 2024. e-Pub 2024. PMID: 39148489.
7. Gillard AG, Shin DH, Hampton LA, Lopez-Rivas A, Parthasarathy A, Fueyo J, Gomez-Manzano C. Targeting Innate Immunity in Glioma Therapy. Int J Mol Sci 25(2), 2024. e-Pub 2024. PMID: 38256021.
8. He, J, Munir, F, Ragoonanan, D, Zaky, W, Khazal, SJ, Tewari, P, Fueyo-Margareto, J, Gomez-Manzano, C, Jiang, H. Combining CAR T Cell Therapy and Oncolytic Virotherapy for Pediatric Solid Tumors. Immuno 3(1):37-56, 2023. e-Pub 2023.
9. Shin DH, Gillard A, Van Wieren A, Gomez-Manzano C, Fueyo J. Remission of liquid tumors and SARS-CoV-2 infection: A literature review. Mol Ther Oncolytics 26:135-140, 2022. e-Pub 2022. PMID: 35702422.
10. Shin DH, Nguyen T, Ozpolat B, Lang F, Alonso M, Gomez-Manzano C, Fueyo J. Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy. J Immunother Cancer 9(4), 2021. e-Pub 2021. PMID: 33795384.
11. Jiang H, Conrad C, Fueyo J, Gomez-Manzano C, Liu TJ. Oncolytic adenoviruses for malignant glioma therapy. Front Biosci 8:d577-88, 2003. e-Pub 2003. PMID: 12700119.

Other Articles

1. Godoy-Vitorino, F, Borrero, M, Pérez-Santiago, J, García-García, R, Gomez-Manzano, C Connecting Innovation and Trust through Translational Sciences – A Need for a Community Focus and Effective Education Strategies. Puerto Rico Health Sciences Journal (PRHSJ) 44(3):185-188, 2025. PMID: 41026590.
2. Parthasarathy A, Frost M, He J, Alonso M, Lang FF, Gomez-Manzano C, Fueyo J Harnessing Oncolytic Adenoviruses for Targeted Diffuse Midline Glioma Therapy. ChadTough Defeat DIPG Foundation 2025 Research Workshop, 2025.

Editorials

1. Youssef GC, Gomez-Manzano C, Sawaya R, Fueyo J. Antitumor immune response during glioma virotherapy. Neuro Oncol 21(9):1087-88, 2019. PMID: 31348516.
2. Fueyo J, Alonso MM, Parker Kerrigan BC, Gomez-Manzano C. Linking inflammation and cancer: the unexpected SYK world. Neuro Oncol 20(5):582-583, 2018. PMID: 29635349.
3. Fueyo J, Hossain MB, Nguyen T, Gomez-Manzano C. Normalizing tumoral vessels to treat cancer: an out-of-the-box strategy involving TIE2 pathway. Transl Cancer Res 6(Suppl 2):S317-320, 2017. PMID: 28944168.
4. Conrad CA, Fueyo J, Gomez-Manzano C. Intratumoral heterogeneity and intraclonal plasticity: from warburg to oxygen and back again. Neuro Oncol 16(8):1025-6, 2014. PMID: 25002413.

Abstracts

1. Jiang H, He J, Duran A, Godina Riera CS, Shin DH, Parthasarathy A, Lopez-Rivas AR, Gillard AG, Lang F, Manzano CG, Fueyo J. Oncolytic Adenoviruses Induce Tertiary Lymphoid Structures in Brain Tumors to Promote Durable Antitumor Immunity. Society of Immunotherapy of Cancer (SITC 2026). e-Pub 2026.
2. Gillard A, Shin DH, Parthasarathy A, Lopez-Rivas A, Jiang H, Singh S, Frost M, Fan X, Alvarez-Breckenridge C, Lang F, Alonso M, Fueyo J, Gomez-Manzano C. A Novel Sensor of Adenovirus and Immune Regulator during oncolytic adenovirotherapy. International Cancer Neuroscience Symposium 2026. e-Pub 2026.
3. Lopez-Rivas AR, Shin DH, Parthasarathy A, Gillard AG, Solbes C, Duran A, Gumin J, Alvarez-Breckenridge C, Lang FF, Fueyo J, Gomez-Manzano C. Combining JAK inhibition with oncolytic virotherapy to reprogram immunosuppressive macrophages in glioblastoma. International Cancer Neuroscience Symposium 2026. e-Pub 2026.
4. Parthasarathy A, Frost M, Gillard A, Shin DH, Rivas AL, Jiang H, Fan X, Rivera AM, Riera CS, Gomez-Manzano C, Fueyo J. Targeting P300/CBP boosts anti-tumor immune response driven by Delta-24-RGD in pediatric Diffuse Midline Gliomas. International Cancer Neuroscience Symposium 2026. e-Pub 2026.
5. Shin DH, Gillard A, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alonso M, He J, Nguyen D, Alvarez-Breckenridge C, Ene C, Lang F, Gomez-Manzano C, Fueyo J. T cell receptor diversity is a predictor of therapy response in patients with gliomas treated with Delta-24-RGD. Neuro Oncol 27(Supplement_5):211 [Rapid Oral Presentation], 2025. e-Pub 2025.
6. Wu X, Ledbetter D, Wang W, Singh S, Gumin J, Fan X, Gillard A, Shin DH, Jiang H, Zhao B, Akdemir K, Conley A, Lazar A, Tatsui C, Lang F, Gomez-Manzano C, Fueyo J, Rhines L, Alvarez-Breckenridge C. The oncolytic adenovirus Delta-24-RGD achieves antitumor polarization of the chordoma tumor microenvironment in human and murine models of chordoma. Neuro Oncol 27(Supplement_5):342, 2025. e-Pub 2025.
7. de Larraya JGP, Casares N, Giraldez M, Serrano M, Bejarano B, Dominguez P, Mbongo C, Andrea CD, Gonzalez-Huarriz M, Ausejo-Mauleon I, Honorato C, Martinez-Simon A, Fueyo J, Gomez-Manzano C, Patiño A, Alonso MM. Phase I Trial of Single Intratumoral Injection of DNX-2440 Oncolytic Adenovirus in Recurrent Glioblastoma Patients. Neuro Oncol 27(Supplement_5):137, 2025. e-Pub 2025.
8. Lopez-Rivas AR, Gillard AG, Parthasarathy A, Shin DH, Frost M, He J, Jiang H, Fan X, Rubio-Ramos S, Duran A, Alonso MM, Lang FF, Alvarez-Breckenridge C, Fueyo J, Gomez-Manzano C. JAK inhibition enhances viroimmunotherapy of gliomas: targeting JAK-guided immunosuppressive pathways. Neuro Oncol 27(Supplement_5):213-214 [Best Poster Award], 2025. e-Pub 2025.
9. Zaman MF, Singh S, Pirani AM, Hossain A, Gumin J, Ledbetter D, Milutinovic B, Fueyo-Margareto J, Gomez-Manzano C, Lang FF. A New View of Microvascular Proliferation: PDGFRB+ Perivascular Stromal Cells Drive MVP Formation, Immunosuppression and Stemness in Glioblastoma. Neuro Oncol 27(Supplement_5):457 [Oral Platform], 2025. e-Pub 2025.
10. Du Y, Singh S, Duran A, Ban K, Wu X, Ene C, Gumin J, Jiang H, Peng D, Gomez J, Sebastian M, Nayyar N, Brastianos P, Tawbi H, Davies M, Lang F, Gomez-Manzano C, Fueyo-Margareto J, Alvarez-Breckenridge C. The oncolytic adenovirus RGDOX sensitizes the anti-tumor efficacy of immune checkpoint blockades in murine melanoma brain metastases models. Neuro Oncol 27(Supplement_5):345, 2025. e-Pub 2025.
11. Lang FF, Shpall E, Weinbereg JS, Ene C, Chen S, Young C, Kamiya C, Fueyo J, Gomez-Manzano C, Peter K. Phase I trial of mesenchymal stem cells carrying Delta-24-RGD given intraarterially in recurrent glioma: Early report. Neuro Oncol 27(Supplement_5):425, 2025. e-Pub 2025.
12. Gillard A, Shin DH, Parthasarathy A, Lopez-Rivas A, Jiang H, He J, Frost M, Fan X, Xu BL, Alvarez-Breckenridge C, Lang F, Alonso M, Fueyo J, Gomez-Manzano C. Uncovering alternative innate immunity pathways in glioma viroimmunotherapy. Neuro Oncol 27(Supplement_5):217, 2025. e-Pub 2025.
13. Shaim H, Jiang XR, Shanley M, Rafei H, Kang J, Hsu Y, Fan H, Zhang P, Basar R, Daher M, Liang Q, Xiong D, Gumin J, Kotapali V, Jones CM, Gilbert AL, Muniz-Feliciano L, Deyter GM, Banerjee P, Kaplan M, Mendt M, Moore M, Li Y, Fang D, Arachya S, Biederstadt I, Jiang H, Uprety N, Shrestha R, Jia B, Phadatare PR, Bierderstadt A, Daniels P, Munir M, Banjo O, Mohanty V, Dou J, Jiang X, Shpall EJ, Chen K, Jain AK, Lang F, Gomez-Manzano C, Fueyo J, Rezvani K. Oncolytic viruses induce sustained anti-tumor cytotoxicity in NK cells through AP-1 and IRF pathways activation. American Association for Cancer Research (AACR) Annual Meeting 2026. e-Pub 2025.
14. Lopez-Rivas AR, Gillard AG, Parthasarathy A, Shin DH, Morales-Rivera A, Solbes C, Duran A, Gumin J, Alvarez-Breckenridge C, Alonso MM, Lang FF, Fueyo J, Gomez-Manzano C. JAK inhibition enhances virotherapy in gliomas by modulating interferon-driven resistance. American Association of Cancer Research (AACR) Annual Meeting 2026. e-Pub 2025.
15. Lopez-Rivas AR, Shin DH, Parthasarathy A, Gillard A, Duran A, Gumin J, Alvarez-Breckenridge C, Lang FF, Fueyo J, Gomez-Manzano C. JAK inhibition modulates polarization of macrophages to enhance viroimmunotherapy against gliomas. Nature Conferences - The Tumor Ecosystem: From Bench to Clinic and Back, 2025. e-Pub 2025.
16. Parthasarathy A, Frost M, Gillard A, Shin DH, Rivas AL, Jiang H, Fan X, Rivera AM, Riera CS, Gomez-Manzano C, Fueyo J. P300/CBP Blockade Boosts Therapeutic Efficacy of Delta-24-RGD Against Diffuse Midline Glioma. Nature Conferences - The Tumor Ecosystem: From Bench to Clinic and Back, 2025. e-Pub 2025.
17. Lopez-Rivas AR, Gillard AG, Parthasarathy A, Shin DH, Frost M, He J, Jiang H, Fan X, Rubio-Ramos S, Duran A, Alonso MM, Lang FF, Alvarez-Breckenridge C, Fueyo J, Gomez-Manzano C. Ruxolitinib enhances viroimmunotherapy of gliomas: targeting JAK-guided immunosuppressive pathways. 2025 WFNOS and SNO Annual Meeting, 2025. e-Pub 2025.
18. Gillard A, Shin DH, Parthasarathy A, Lopez-Rivas A, Jiang H, He J, Frost M, Fan X, Xu BL, Alvarez-Breckenridge C, Lang F, Alonso M, Fueyo J, Gomez-Manzano C. Uncovering alternative innate immunity pathways in glioma viroimmunotherapy. 2025 WFNOS and SNO Annual Meeting, 2025. e-Pub 2025.
19. Gillard A, Shin DH, Parthasarathy A, Lopez-Rivas A, Jiang H, He J, Frost M, Fan X, Xu BL, Alvarez-Breckenridge C, Lang F, Alonso M, Fueyo J, Gomez-Manzano C. Novel immunoregulatory roles of NONO and cGAMP in glioma viroimmunotherapy. Nature Conferences - The Tumor Ecosystem: From Bench to Clinic and Back, 2025. e-Pub 2025.
20. Morales-Rivera A, Fueyo J, Gomez-Manzano C, Gillard A, Lopez-Rivas A, Parthsarathy A, Jiang H, Singh S, Barrio IM, Akdemir K, Reuben A, Ene C, Hudson W, Lang F, Shin DH. Analysis of T Cell Receptors Reveals Biomarkers of Response in Virotherapy-Treated Gliomas. Nature Conferences - The Tumor Ecosystem: From Bench to Clinic and Back, 2025. e-Pub 2025.
21. Shin DH, Gillard A, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alonso M, He J, Nguyen D, Alvarez-Breckenridge C, Ene C, Lang F, Gomez-Manzano C, Fueyo J. T cell receptor diversity is a predictor of therapy response in patients with gliomas treated with Delta-24-RGD. 2025 WFNOS and SNO Annual Meeting, 2025. e-Pub 2025.
22. He J, Duran A, Fan X, Shin DH, Frost M, Parthasarathy A, Lopez-Rivas A, Gillard A, Gumin J, Lang F, Gomez-Manzano C, Fueyo J, Jiang Hong. Arming Oncolytic Adenoviruses with Immune Stimulators: Enhancing CAR T Cell Therapy for Malignant Primary and Metastatic Brain Tumors. Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting 13(Suppl_2):308, 2025. e-Pub 2025.
23. Jiang H, He J, Duran A, Fan X, Shin DH, Frost M, Parthasarathy A, Lopez-Rivas A, Gillard AG, Gumin J, Lang FF, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus armed with immune stimulators: a promising partner for CAR T cell therapy in primary and metastatic malignant brain tumors. 2025 WFNOS and SNO Annual Meeting 27(Suppl_5):364, 2025. e-Pub 2025.
24. Parthasarathy A, Frost M, He J, Gillard A, Shin DH, Lopez A, Jiang H, Fan X, Venneti S, Phoenix T, Alonso M, Lang F, Gomez-Manzano C, Fueyo J. Novel therapy for diffuse midline glioma: Targeting oncohistone drivers with P300/CBP inhibition and Delta-24-RGD. 2025 WFNOS and SNO Annual Meeting 27(Suppl_5):456 [Best Poster Award], 2025. e-Pub 2025.
25. Shin DH, Gillard A, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alonso M, He J, Nguyen D, Alvarez-Breckenridge C, Ene C, Lang F, Gomez-Manzano C, Fueyo J. T cell receptor diversity is a predictor of therapy response in patients with gliomas treated with Delta-24-RGD. Cancer Neurosciences Program Scientific Retreat. e-Pub 2025.
26. Gillard A, Shin DH, Parthasarathy A, Lopez-Rivas A, Jiang H, He J, Frost M, Fan X, Xu BL, Alvarez-Breckenridge C, Lang F, Alonso M, Fueyo J, Gomez-Manzano C. NONO: A Novel Sensor of Adenovirus and Immune Regulator. Cancer Neuroscience Program Scientific Retreat. e-Pub 2025.
27. He J, Parthasarathy A, Frost M, Garcia Moure M, Shin DH, Lopez-Rivas A, Gillard A, Duran A, Fan X, Phoenix T, Lang FF, Alonso M, Fueyo J, Gomez-Manzano C, Jiang H. Locoregional Therapy with Immune Co-stimulator-armed Oncolytic Adenovirus for Diffuse Midline Glioma. 2025 SNO Pediatric Neuro-Oncology Conference 1(Supplement_1), 2025. e-Pub 2025.
28. He J, Parthasarathy A, Shin DH, Garcia Moure M, Lopez-Rivas A, Gillard A, Duran A, Fan X, Phoenix T, Lang FF, Alonso M, Fueyo J, Gomez-Manzano C, Jiang H. Effects of armed oncolytic adenovirus on immunotherapy for primary and metastatic brain tumors. 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, 2025. e-Pub 2025.
29. Parthasarathy A, Frost M, He J, Garcia Moure M, Gillard A, Shin DH, Lopez-Rivas A, Alonso M, Gomez-Manzano C, Fueyo J. Combining P300/CBP inhibition with Delta-24-RGDenhances the anti-tumor effect in Diffuse Midline Glioma. 2025 SNO Pediatric Neuro-Oncology Conference, 2025. e-Pub 2025.
30. He J, Parthasarathy A, Frost M, Garcia Moure M, Shin DH, Lopez-Rivas A, Gillard A, Duran A, Fan X, Phoenix T, Lang FF, Alonso M, Fueyo J, Jiang H, Gomez-Manzano C. Enhancing CAR T Cell Therapy for Diffuse Midline Glioma via Locoregional Delivery of Armed Oncolytic Adenovirus. ChadTough Defeat DIPG Foundation 2025 Research Workshop, 2025. e-Pub 2025.
31. Gillard A, Shin DH, Laspidea V, Singh SK, Hampton LA, Jiang H, Fan X, Lopez-Rivas A, Parthasarathy A, He J, Moure MG, Fueyo J, Alonso MM, Gomez-Manzano C. Unlocking the therapeutic potential of glioma virotherapy: NONO and cGAMP as key regulators of innate immune activation. Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting 2024, 2024. e-Pub 2024.
32. Lopez-Rivas A, Gillard A, Parthasarathy A, Shin DH, Moure MG, Hampton LA, He J, Jiang H, Fan X, Wainwright DA, Quintana F, Fueyo J, Gomez-Manzano C. Targeting the immunometabolic factor AhR boosts glioma viroimmunotherapy. Society for the Immunotherapy of Cancer (SITC) 39th Annual Meeting 2024, 2024. e-Pub 2024.
33. Jiang XR, Rafei H, Basar R, Daher M, Liang Q, Biederstadt I, Zhang P, Xiong D, Kang J, Gumin J, Shanley M, Jones CM, Gilbert AL, Shaim H, Muniz-Feliciano L, Deytter GM, Banerjee P, Moore M, Li Y, Fang D, Arachya S, Jiang H, Uprety N, Shrestha R, Jia B, Daniel P, Munir M, Banjo O, Shpall EJ, Jain AK, Chen K, Lang FF, Gomez-Manzano C, Fueyo J, Rezvani K. Oncolytic viruses induce sustained anti-tumor cytotoxicity in NK cells. Society for the Immunotherapy of Cancer (SITC) 39th Annual Meeting 2024, 2024. e-Pub 2024.
34. Jiang H, He J, Duran A, Fan X, Shin DH, Parthasarathy A, Gillard A, Lopez-Rivas A, Moure MG, Lang FF, Gomez-Manzano C, Fueyo J. Antitumor activity of CAR T cells potentiated by oncolytic adenoviruses armed with immune stimulators. Society for the Immunotherapy of Cancer (SITC) 39th Annual Meeting 2024, 2024. e-Pub 2024.
35. Parthasarathy A, Moure MG, He J, Gillard A, Paparella A, Shin DH, Lopez-Rivas A, Jiang H, Fan X, Hampton LA, Delaney J, Phoenix TN, Lang FF, Young NL, Alonso MM, Gomez-Manzano C, Fueyo J. Viroimmunotherapy combined with acetylation suppression: advanced therapeutics for pediatric diffuse midline gliomas. Society for the Immunotherapy of Cancer (SITC) 39th Annual Meeting 2024, 2024. e-Pub 2024.
36. Jiang H, He J, Duran A, Fan X, Shin DH, Parthasarathy A, Gillard A, Lopez-Rivas A, Moure MG, Lang FF, Gomez-Manzano C, Fueyo J. Anti-tumor activity of a new oncolytic adenovirus Delta-24-RGDOX-IL15 co-expressing OX40L and IL15. Society for the Immunotherapy of Cancer (SITC) 39th Annual Meeting 2024, 2024. e-Pub 2024.
37. Gillard A, Shin DH, Jiang H, Fan X, Laspidea V, He J, Lopez-Rivas A, Parthasarathy A, Alonso MM, Lang FF, Fueyo J, Gomez-Manzano C. Targeting NONO in glioma viroimmunotherapy. Society of Neuro-Oncology (SNO) 29th Annual Meeting and Education Day 2024, 2024. e-Pub 2024.
38. Moure M, Lopez-Rivas A, Parthasarathy A, Shin DH, Jiang H, He J, Tran HN, Yun K, Hernandez-Osuna R, Labiano S, Alonso MM, Phoenix T, Wainwright D, Fueyo J, Gomez-Manzano C. Cracking the role of oncometabolites in viroimmunotherapy for pediatric malignant brain tumors. Society of Neuro-Oncology (SNO) 29th Annual Meeting and Education Day 2024, 2024. e-Pub 2024.
39. Garcia Moure M, Lopez-Rivas A, Parthasarathy A, Gillard A, Shin DH, Jiang H, He J, Tran HN, Yun K, Hernandez-Osuna R, Labiano S, Alonso MM, Phoenix T, Wainwright D, Fueyo J, Gomez-Manzano C. Modulating tumor metabolism to overcome mechanisms of resistance to viroimmunotherapy in pediatric brain tumors. Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting 2024, 2024. e-Pub 2024.
40. Shin DH, Ozpolat B, Gillard A, Moure M, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alemany R, Alonso MM, He J, Ene C, Al-Atrash G, Lang FF, Gomez-Manzano C, Fueyo J. Winning the tug of war between virus and tumor immunodominance in gliomas treated with oncolytic adenoviruses using tolerogenic strategies. Society of Neuro-Oncology (SNO) 29th Annual Meeting and Education Day 2024, 2024. e-Pub 2024.
41. Shin DH, Ozpolat B, Gillard A, Moure M, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alemany R, Alonso MM, He J, Ene C, Al-Atrash G, Lang FF, Gomez-Manzano C, Fueyo J. Refocusing on tumors: overcoming antiviral immunity in oncolytic virotherapy. Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting 2024, 2024. e-Pub 2024.
42. Parthasarathy A, Moure M, He J, Gillard A, Paparella A, Shin DH, Lopez-Rivas A, Jiang H, Fan X, Hampton L, Phoenix T, Lang FF, Young N, Alonso MM, Gomez-Manzano C, Fueyo J. Acetylation Suppression Meets Oncolytic Viruses for the Treatment of Pediatric Diffuse Midline Glioma. Society of Neuro-Oncology (SNO) 29th Annual Meeting and Education Day 2024, 2024. e-Pub 2024.
43. Lopez-Rivas A, Gillard A, Parthasarathy A, Shin DH, Moure M, Hampton L, He J, Jiang H, Fan X, Wainwright D, Quintana F, Fueyo J, Gomez-Manzano C. Targeting the AhR immunometabolic hub during viroimmunotherapy of gliomas. Society of Neuro-Oncology (SNO) 29th Annual Meeting and Education Day 2024, 2024. e-Pub 2024.
44. Gillard A, Shin DH, Lang FF, Alonso MM, Fueyo J, Gomez-Manzano C. Elucidating Novel Innate Immune Mechanisms in Glioma Viroimmunotherapy. 16th Annual International Oncolytic Virotherapy Conference (IOVC 2024), 2024. e-Pub 2024.
45. Parthasarathy A, Moure MG, He J, Jiang H, Frost M, Lang FF, Alonso MM, Gomez-Manzano C, Fueyo J. Targeting P300-mediated acetylation in Delta-24-RGD-treated diffuse midline gliomas. 16th Annual International Oncolytic Virotherapy Conference (IOVC) 2024, 2024. e-Pub 2024.
46. Moure M, Lopez-Rivas A, Parthasarathy A, Gillard A, Shin DH, Jiang H, He J, Tran HN, Yun K, Hernandez-Osuna R, Labiano S, Alonso MM, Phoenix TN, Wainwright DA, Fueyo J, Gomez-Manzano C. Exploring oncometabolite pathways in pediatric brain tumors as an actionable target to improve viroimmunotherapy. EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2024, 2024. e-Pub 2024.
47. Shin DH, Ozpolat B, Gillard A, Moure M, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alemany R, Alonso M, He J, Ene C, Al-Atrash G, Lang FF, Gomez-Manzano C, Fueyo J. Nanoparticle-induced virus immune tolerance during oncolytic therapy of gliomas. EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2024, 2024. e-Pub 2024.
48. la Nava DD, Ausejo-Mauleon I, Nazarian J, Mueller S, Allen JE, Koschmann C, Venneti S, Dun MD, Gomez-Manzano C, Fueyo J, Patiño-Garcia A, Alonso MM. ONC201 Combined with the Oncolytic Adenovirus Delta-24-RGD as a new Therapeutic Regime for Pediatric High-Grade and Diffuse Midline Gliomas. International Symposium on Pediatric Neuro-Oncology (ISPNO 2024) 26(Supplement_4):0, 2024. e-Pub 2024.
49. Parthasarathy A, Garcia-Moure M, He J, Shin DH, Gillard AG, Lopez-Rivas A, Hampton LA, Fan X, Jiang H, Lang FF, Alonso MM, Gomez-Manzano C, Fueyo J. Targeting hyperacetylation in pediatric diffuse midline gliomas using oncolytic adenoviruses. International Symposium on Pediatric Neuro-Oncology (ISPNO 2024) 26(Supplement_4):0, 2024. e-Pub 2024.
50. Meléndez-Vázquez NM, Fan X, Fueyo J, Gomez-Manzano C, Godoy-Vitorino F. Levels of isobutyric acid from gut butyrate-producing taxa are associated to Delta-24-RGDOX efficacy against malignant glioma. American Association for Cancer Research (AACR) Annual Meeting 2024, 2024. e-Pub 2024.
51. Shin DH, Jiang H, Gillard A, Fan X, Singh S, Lopez-Manzano A, He J, Gumin J, Lang FF, Gomez-Manzano C, Fueyo J. A chimeric oncolytic adenovirus circumvents neutralizing antibodies developed by patients with recurrent glioblastoma treated with Delta-24-RGD. Neuro Oncol, 2023. e-Pub 2023.
52. Shin DH, Lang FF, Jiang H, Gillard A, Nguyen T, Fan X, Singh S, Lopez-Rivas A, Parthasarathy A, Aleman D, Hampton LA, Ene C, Gumin J, Alonso MM, Fueyo J, Gomez-Manzano C. Chimeric hexon adenovirus evades neutralizing antibodies from patients treated with Delta-24-RGD oncolytic adenovirus. Mol Ther Oncol, 2023. e-Pub 2023.
53. Lang FF, Zadeh G, Nassiri F, Nguyen TT, Moure M, Alonso MM, Gomez-Manzano C, Fueyo J. Combination of oncolytic adenovirus with modulators of the immune checkpoints. Mol Ther Oncol, 2023. e-Pub 2023.
54. Gillard A, Shin DH, Jiang H, Fan X, Laspidea V, He J, Lopez-Rivas A, Parthasarathy A, Alonso MM, Lang FF, Fueyo J, Gomez Manzano C. New Immunomodulatory roles of NONO pathway during glioma virotherapy. JITC 11(Suppl 1):A1206, 2023. e-Pub 2023.
55. Shin DH, Lang FF, Jiang H, Gillard A, Nguyen TT, Fan X, Singh S, Lopez-Rivas A, Parthasarathy A, Aleman D, Hampton LA, Ene C, Gumin J, Alonso MM, Fueyo J, Gomez-Manzano C. Chimeric hexon adenovirus evades neutralizing antibodies from patients treated with Delta-24-RGD oncolytic adenovirus. 15th Annual International Oncolytic Virotherapy Conference (IOVC 2023), 2023. e-Pub 2023.
56. Shin DH, Jiang H, Gillard A, Fan X, Singh S, Lopez-Manzano A, He J, Gumin J, Lang FF, Gomez-Manzano C, Fueyo J. A chimeric oncolytic adenovirus circumvents neutralizing antibodies developed by patients with recurrent glioblastoma treated with Delta-24-RGD. 28th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO 2023), 2023. e-Pub 2023.
57. Lang FF, Zadeh G, Nassiri F, Nguyen TT, Moure M, Alonso MM, Gomez-Manzano C, Fueyo J. Combination of oncolytic adenovirus with modulators of the immune checkpoints. 15th Annual International Oncolytic Virotherapy Conference (IOVC 2023), 2023. e-Pub 2023.
58. Gillard A, Shin DH, Jiang H, Fan X, Laspidea V, He J, Lopez-Rivas A, Parthasarathy A, Alonso MM, Lang FF, Fueyo J, Gomez-Manzano C. Targeting NONO in glioma viroimmunotherapy. 28th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO 2023), 2023. e-Pub 2023.
59. Meléndez-Vázquez NM, Nguyen T, Fueyo J, Gomez-Manzano C, Godoy-Vitorino F. Bacterial gut biota is associated with oncolytic viral therapy efficacy against glioblastoma. Forward Research & Innovation Summit: Science & Space Edition, 2023. e-Pub 2023.
60. Gillard A, Shin DH, Laspidea V, Singh S, Jiang H, Fan X, Yi Y, He J, Lopez-Rivas A, Lang FF, Fueyo J, Gomez-Manzano C. Exploring NONO as a potential innate immune sensor for oncolytic adenovirus in glioma treatment. Cancer Immunol Res, 2023. e-Pub 2023.
61. Shin DH, Jiang H, Gillard A, Fan X, Singh S, Lopez-Rivas A, He J, Parthasarathy A, Gumin J, Lang FF, Gomez-Manzano C, Fueyo J. Single Versus Multiple Injections of Oncolytic Adenoviruses in a Clinical Trial Suggests Strategies to Improve Cancer Virotherapy Through Immune-Evasion Strategies. Cancer Immunol Res, 2023. e-Pub 2023.
62. Gállego-Pérez de Larraya J, García-Moure M, de la Nava D, González-Huárriz M, Labiano S, Zalacaín M, Marrodán L, Laspidea V, Ausejo I, Hervás I, Puigdelloses M, Esparragosa I, Giráldez M, Serrano M, Domínguez P, Bejarano B, Tejada S, Díez-Valle R, Fueyo J, Gomez-Manzano C, Patiño A, Alonso MM. Phase I trial of DNX-2440 oncolytic adenovirus in patients with first or second recurrence of glioblastoma: preliminary results. Neuro Oncol, 2023. e-Pub 2023.
63. Larray J, Moure M, Nava D, González-Huárriz M, Labiano S, Zalacain M, Marrodan L, Laspidea V, Ausejo I, Hervas I, Puigdelloses M, Esparragosa I, Giráldez M, Serrano M, Domínguez P, Bejarano B, Tejada S, Díez-Valle R, Fueyo J, Gomez-Manzano C, Patiño A, Alonso MM. Phase I trial of DNX-2440 oncolytic adenovirus in patients with first or second recurrence of glioblastoma: preliminary results. European Association of Neuro-Oncology (EANO 2023), 2023. e-Pub 2023.
64. Shin DH, Jiang H, Gillard A, Fan X, Singh S, Lopez-Rivas A, He J, Parthasarathy A, Gumin J, Lang FF, Gomez-Manzano C, Fueyo J. Single Versus Multiple Injections of Oncolytic Adenoviruses in a Clinical Trial Suggests Strategies to Improve Cancer Virotherapy Through Immune-Evasion Strategies. 7th International Cancer Immunotherapy Conference: Translating Science into Survival (CICON 2023), 2023. e-Pub 2023.
65. Gillard A, Shin DH, Laspidea V, Singh S, Jiang H, Fan X, Yi Y, He J, Lopez-Rivas A, Lang FF, Fueyo J, Gomez-Manzano C. Exploring NONO as a potential innate immune sensor for oncolytic adenovirus in glioma treatment. 7th International Cancer Immunotherapy Conference: Translating Science into Survival (CICON 2023), 2023. e-Pub 2023.
66. Meléndez-Vázquez NM, Sohoni S, Van Wieren A, Fueyo J, Gomez-Manzano C, Godoy-Vitorino F. Changes in the gut microbiota associated with oncolytic virotherapy efficacy in a gastric cancer murine model. Cancer Res, 2023. e-Pub 2023.
67. Gillard A, Shin DH, Laspidea V, Singh S, Jiang H, Fan X, Yi Y, He J, Lopez-Rivas A, Lang FF, Fueyo J, Gomez-Manzano C. Implications for virotherapy: a new adenovirus capsid sensor. Cancer Res, 2023. e-Pub 2023.
68. Gillard A, Shin DH, Laspidea V, Singh S, Jiang H, Fan X, Yi Y, He J, Lopez-Rivas A, Lang FF, Fueyo J, Gomez-Manzano C. Implications for virotherapy: a new adenovirus capsid sensor. American Association for Cancer Research Annual Meeting (AACR 2023), 2023. e-Pub 2023.
69. Meléndez-Vázquez NM, Sohoni S, Wieren A, Fueyo J, Gomez-Manzano C, Godoy-Vitorino F. Changes in the gut microbiota associated with oncolytic virotherapy efficacy in a gastric cancer murine model. American Association for Cancer Research Annual Meeting (AACR 2023), 2023. e-Pub 2023.
70. Shin DH, Jiang H, Ozpolat B, Gillard A, Kim D, Nguyen TT, Fan X, Yi Y, Ban K, Alemany R, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Immune tolerance for viral antigens facilitates tumoral epitope spreading during oncolytic virotherapy. Neuro Oncol, 2023. e-Pub 2023.
71. Gillard A, Shin DH, Laspidea V, Jiang H, Fan X, Yi Y, Hu J, Alonso MM, Lang FF, Fueyo J, Gomez-Manzano C. New insights on innate immune pathways sensing oncolytic adenoviruses. Neuro Oncol, 2023. e-Pub 2023.
72. Shin DH, Jiang H, Ozpolat B, Gillard A, Kim D, Nguyen TT, Fan X, Yi Y, Ban K, Alemany R, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Immune tolerance for viral antigens facilitates tumoral epitope spreading during oncolytic virotherapy. International Conference on Brain Tumor Research and Therapy (ICBTRT 2023), 2023. e-Pub 2023.
73. Gillard A, Shin DH, Laspidea V, Jiang H, Fan X, Yi Y, Hu J, Alonso MM, Lang FF, Fueyo J, Gomez-Manzano C. New insights on innate immune pathways sensing oncolytic adenoviruses. International Conference on Brain Tumor Research and Therapy (ICBTRT 2023), 2023. e-Pub 2023.
74. Jiang H, Shin DH, Yi Y, Fan X, Gumin J, Gillard A, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Localized intratumoral treatment with adoptive T cell therapy followed by oncolytic adenovirus Delta-24-RGDOX induces sustainable regression of disseminated solid tumors through antigen spread. Neuro Oncol 24(suppl_7):vii231, 2022. e-Pub 2022.
75. Jiang H, Shin DH, Yi Y, Fan X, Gumin J, Gillard A, He J, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Antigen spread mediated by oncolytic adenovirus Delta-24-RGDOX during intratumoral adoptive T cell therapy in immunocompetent mice with disseminated tumors. JITC, 2022. e-Pub 2022.
76. Gillard A, Dh S, Laspidea V, Singh SK, Jiang H, Kim D, Fan X, Yi Y, Lang F, Alonso M, Fueyo J, Gomez-Manzano C. NONO is a new adenovirus sensor: Implication for virotherapy. Neuro Oncol 24(suppl_7):vii133, 2022. e-Pub 2022.
77. Shin DH, Jiang H, Gillard A, Kim D, Nguyen T, Sohoni S, Fan X, Yi Y, Ban K, Alemany R, Alonso M, Lang F, Gomez-Manzano C, Ozpolat B, Fueyo J. Nanoparticle treatment rebalances immunodominance of anti-virus immunity to enhance anti-tumor immunity during oncolytic adenovirus therapy in solid tumors. Neuro Oncol 24(suppl_7):vii139-vii140, 2022. e-Pub 2022.
78. Nguyen TN, Shin DH, Kim D, Singh SK, Jiang H, Gillard A, Fan X, Yi Y, Gumin J, Lang FF, Alvarez-Breckenridge C, Alonso MM, Godoy-Vitorino F, Zhai L, Ladomersky E, Lauing KL, Wainwright DA, Fueyo J, Gomez-Manzano C. Examination of the tumor microenvironment of gliomas treated with viroimmunotherapy reveals the production of oncometabolites leading to new therapeutic strategies. Neuro Oncol 24(suppl_7):vii223, 2022. e-Pub 2022.
79. Jiang H, Shin DH, Yi Y, Fan X, Gumin J, Gillard A, He J, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Antigen spread mediated by oncolytic adenovirus Delta-24-RGDOX during intratumoral adoptive T cell therapy in immunocompetent mice with disseminated tumors. Society for Immunotherapy of Cancer 37th Annual Meeting (SITC 2022), 2022. e-Pub 2022.
80. Meléndez-Vázquez N, Gomez-Manzano C, Nguyen T, Fueyo J, Godoy-Vitorino F. Association between the gut microbiome and oncolytic viral therapy efficacy against glioblastoma. Science, 2022. e-Pub 2022.
81. Melendez-Vazquez N, Gomez-Manzano C, Nguyen TT, Fueyo J, Godoy-Vitorino F. Association between the gut microbiome and oncolytic viral therapy efficacy against glioblastoma. American Association for the Advancement (AAAS) of Science Caribbean Division Annual Meeting 2022, 2022. e-Pub 2022.
82. Melendez-Vazquez NM, Gomez-Manzano C, Nguyen TT, Fueyo J, Godoy-Vitorino F. Gut bacterial changes related to the efficacy of viroimmunotherapy against glioblastoma. American Society for Microbiology - Microbe 2022 Book of Abstracts, 2022. e-Pub 2022.
83. Melendez-Vazquez NM, Gomez-Manzano C, Nguyen TT, Fueyo J, Godoy-Vitorino F. Gut bacterial changes related to the efficacy of viroimmunotherapy against glioblastoma. American Society for Microbiology - Microbe 2022, 2022. e-Pub 2022.
84. Gupta S, Laspidea V, Fueyo J, Zaky W, Becher O, Nguyen TT, Shin DH, Jiang H, Sohoni SS, Fan X, Yi Y, Gumin J, Lang FF, Gomez-Manzano C, Alonso MM. Armed oncolytic adenovirus as experimental therapy for pediatric malignant gliomas. Pediatr Blood Cancer, 2022. e-Pub 2022.
85. Gupta S, Laspidea V, Fueyo J, Zaky W, Becher O, Nguyen TT, Shin DH, Jiang H, Sohoni SS, Fan X, Yi Y, Gumin J, Lang FF, Gomez-Manzano C, Alonso MM. Armed oncolytic adenovirus as experimental therapy for pediatric malignant gliomas. American Society of Pediatric Hematology/Oncology (ASPHO) Conference 2022, 2022. e-Pub 2022.
86. Jiang H, Shin DH, Yi Y, Fan X, Gumin J, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Combining oncolytic adenovirus Delta-24-RGDOX with adoptive T cell therapy in localized treatment induces sustainable regression of disseminated solid tumors through antigen spreading. Cancer Res, 2022. e-Pub 2022.
87. Shin DH, Jiang H, Kim D, Nguyen TT, Sohoni SS, Fan X, Yi Y, Van Wieren AC, Al-Atrash G, Bernatchez C, Alemany R, Alonso MM, Lang FF, Gomez-Manzano C, Ozpolat B, Fueyo J. Redirection of anti-virus immunity towards anti-tumor immunity using nanoparticle-induced immune tolerance for oncolytic adenovirus therapy. Cancer Res, 2022. e-Pub 2022.
88. Nguyen TT, Shin DH, Sohoni SS, Singh SK, Rivera-Molina Y, Jiang H, Fan X, Gumin J, Lang FF, Alvarez-Breckenridge C, Alonso MM, Godoy-Vitorino F, Zhai L, Ladomersky E, Lauing KL, Wainwright DA, Fueyo J, Gomez-Manzano C. RNA-seq analyses reveals remodeling of tumor microenvironment and reversal of glioma resistance to oncolytic viruses by targeting immunometabolism. Cancer Res, 2022. e-Pub 2022.
89. Laspidea V, Labiano S, Gupta S, Jiang H, Ausejo-Mauleon I, de la Nava D, García-Moure M, Marco-Sanz J, Hernández-Osuna R, Becher O, Fueyo J, Patiño-García A, Gomez-Manzano C, Alonso MM. Delta-24-RGDOX oncolytic adenovirus improves the survival by modulating the immune system in DMG models. Cancer Res, 2022. e-Pub 2022.
90. Wieren AC, Sohoni SS, Nguyen TT, Ossimetha A, Rivera-Molina Y, Jiang H, Shin DH, Kim D, Fan X, Yi Y, Melendez-Vazquez NM, Godoy-Vitorino F, Gumin J, Lang FF, Alonso MM, Fueyo J, Gomez-Manzano C. Viroimmunotherapy for solid tumors results in local and abscopal anti-cancer effects and the remodeling of tumor microenvironment. Cancer Res, 2022. e-Pub 2022.
91. Shin DH, Jiang H, Kim D, Nguyen TT, Sohoni SS, Fan X, Yi Y, Wieren AC, Al-Atrash G, Bernatchez C, Alemany R, Alonso MM, Lang FF, Gomez-Manzano C, Ozpolat B, Fueyo J. Redirection of anti-virus immunity towards anti-tumor immunity using nanoparticle-induced immune tolerance for oncolytic adenovirus therapy. American Association for Cancer Research Annual Meeting (AACR 2022), 2022. e-Pub 2022.
92. Wieren AC, Sohoni SS, Nguyen TT, Ossimetha A, Rivera-Molina Y, Jiang H, Shin DH, Kim D, Fan X, Yi Y, Melendez-Vazquez NM, Godoy-Vitorino F, Gumin J, Lang FF, Alonso MM, Fueyo J, Gomez-Manzano C. Viroimmunotherapy for solid tumors results in local and abscopal anti-cancer effects and the remodeling of tumor microenvironment. American Association for Cancer Research Annual Meeting (AACR 2022), 2022. e-Pub 2022.
93. Jiang H, Shin DH, Yi Y, Fan X, Gumin J, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Combining oncolytic adenovirus Delta-24-RGDOX with adoptive T cell therapy in localized treatment induces sustainable regression of disseminated solid tumors through antigen spreading. American Association for Cancer Research Annual Meeting (AACR 2022), 2022. e-Pub 2022.
94. Laspidea V, Labiano S, Gupta S, Jiang H, Ausejo-Mauleon I, Nava D, Moure M, Marco-Sanz J, Hernandez-Osuna R, Becher O, Fueyo J, Patino-Garcia A, Gomez-Manzano C, Alonso MM. Delta-24-RGDOX oncolytic adenovirus improves the survival by modulating the immune system in DMG models. American Association for Cancer Research Annual Meeting (AACR 2022), 2022. e-Pub 2022.
95. Nguyen TT, Shin DH, Sohoni SS, Singh SK, Rivera-Molina Y, Jiang H, Fan X, Gumin J, Lang FF, Alvarez-Breckenridge C, Alonso MM, Godoy-Vitorino F, Zhai L, Ladomersky E, Lauing KL, Wainwright DA, Fueyo J, Gomez-Manzano C. RNA-seq analyses reveals remodeling of tumor microenvironment and reversal of glioma resistance to oncolytic viruses by targeting immunometabolism. American Association for Cancer Research Annual Meeting (AACR 2022), 2022. e-Pub 2022.
96. Shin DH, Jiang H, Ozpolat B, Gillard A, Kim D, Nguyen T, Alemany R, Alonso MM, Lang FF, Fueyo J, Gomez-Manzano C. Strategies to circumvent the antiviral immunity result in enhanced anti-cancer effect of the oncolytic adenovirus Delta-24-RGD. 14th International Oncolytic Virotherapy Conference (IOVC 2022), 2022. e-Pub 2022.
97. Jiang H, Shin DH, Yi Y, Fan X, Gillard A, Gupta S, He J, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Combination of oncolytic adenovirus therapy with adaptive cell therapy enhances systemic anti-tumor immunity. 14th International Oncolytic Virotherapy Conference (IOVC 2022), 2022. e-Pub 2022.
98. Melendez-Vazquez NM, Gomez-Manzano C, Nguyen TT, Fueyo J, Godoy-Vitorino F. Gut bugs matter to oncolytic viral therapy: bacterial changes associated to Delta-24-RGDOX efficacy against malignant glioma. 18th International Symposium on Microbial Ecology (ISME18), 2022. e-Pub 2022.
99. Alonso MM, Fueyo J, Gomez-Manzano C. Translating the Delta-24-platform for Pediatric Brain Tumors. International Oncolytic Virus Conference, November 5-7, 2021 | Sedona, AZ and Virtually, 2021. e-Pub 2021.
100. Gallego J, García-Moure M, Patiño A, Gonzalez-Huarriz M, Van der Lugt J, Astigarraga I, García-Ariza M, Lopez-Ibor B, Jones C, Mackay A, Diez-Valle R, Fueyo J, Gomez-Manzano C, Dobbs J, Ewald B, Alonso M, Tejada S. Safety, efficacy, and survival results from a Phase 1 study of the oncolytic adenovirus DNX-2401 followed by standard of care radiotherapy for newly diagnosed diffuse intrinsic pontine glioma (DIPG). Neuro Oncol 23(Suppl_6):vi50-51, 2021. e-Pub 2021.
101. Jiang H, Shin DH, Sohoni SS, Nguyen TT, Yi Y, Fan X, Gumin J, Singh SK, Lang FF, Gomez-Manzano C, Fueyo J. Sustainable regression of disseminated solid tumors mediated by in situ combinational treatment with adoptive T cell therapy and oncolytic adenovirus Delta-24-RGDOX. JITC, 2021. e-Pub 2021.
102. Jiang H, Shin DH, Sohoni SS, Nguyen TT, Yi Y, Fan X, Gumin J, Singh SK, Lang FF, Gomez-Manzano C, Fueyo J. Sustainable regression of disseminated solid tumors mediated by in situ combinational treatment with adoptive T cell therapy and oncolytic adenovirus Delta-24-RGDOX. Society for Immunotherapy of Cancer Annual Meeting (SITC 2021), 2021. e-Pub 2021.
103. Southward T, Sohoni S, Gomez Manzano C. Killed in Cold Blood: An Exploration of Oncolytic Adenoviruses in Metastatic Breast Cancer. Annual Biomedical Research Conference for Minority Students (ABRCMS 2021), 2021. e-Pub 2021.
104. Southward T, Sohoni S, Gomez Manzano C. Cold Blooded Killers: An Exploration of Oncolytic Adenoviruses in Metastatic Breast Cancer. GCURS Online, 2021. e-Pub 2021.
105. Southward T, Sohoni SS, Gomez-Manzano C. Cold Blooded Killers: An Exploration of Oncolytic Adenoviruses in Metastatic Breast Cancer. Gulf Coast Undergraduate Research Symposium (GCURS 2021), 2021. e-Pub 2021.
106. Melendez-Vazquez N, Nguyen T, Sohoni SS, Ossimetha A, Fueyo J, Gomez-Manzano C, Godoy-Vitorino F. Gut bugs matter to viroimmunotherapy: bacterial changes associated to the efficacy of Delta-24-RGDOX against glioblastoma. ISME-LAT 2021, 2021. e-Pub 2021.
107. Melendez-Vazquez N, Nguyen TT, Sohoni SS, Ossimetha A, Fueyo J, Gomez-Manzano C, Godoy-Vitorino F. Gut bugs matter to viroimmunotherapy: bacterial changes associated to the efficacy of Delta-24-RGDOX against glioblastoma. International Society for Microbial Ecology (ISME) 2021, 2021. e-Pub 2021.
108. García-Moure M, Gallego J, Patiño A, Gonzalez-Huarriz M, Jones C, Mckay A, Van der Lugt J, Hulleman E, de Andrea C, Astigarraga I, García-Ariza M, Lopez-Ibor B, Villalba M, Lang FF, Fueyo J, Gomez-Manzano C, Dobbs J, Diez-Valle R, Alonso MM, Tejada S. Results of a phase 1 study of the oncolytic adenovirus DNX-2401 with radiotherapy for newly diagnosed diffuse intrinsic pontine glioma (DIPG). Neuro Oncol 23(Supplement_1):i47, 2021. e-Pub 2021.
109. de la Nava D, Ausejo-Mauleon I, Laspidea V, Marrodán L, Zalacain M, Herrador-Cañete G, Nazarian J, Mueller S, Allen JE, Fueyo J, Gomez-Manzano C, Gupta S, Patiño A, Alonso MM. The Imipridone ONC201 in Combination with the Oncolytic Adenovirus Delta-24 RGD has a Synergetic Effect in Preclinical Models of PHGGS and DMGS. Neuro Oncol 23(Supplement_1):i20, 2021. e-Pub 2021.
110. Puigdelloses M, Laspidea V, Hambardzumyan D, Chen Z, Gupta S, Gomez-Manzano C, Labiano S, Becher OJ, Woodruff T, Pío R, Ajona D, Pérez-Larraya JG, Alonso MM. Modulating the Myeloid Population in DIPG Models with Oncolytic Virus and Complement Inhibitors Shows Therapeutic Efficacy. Neuro Oncol 23(Supplement_1):i28, i29, 2021. e-Pub 2021.
111. Labiano S, Laspidea V, Garcia-Moure M, Puigdelloses M, Becher O J, Gomez-Manzano C, Fueyo J, Patiño-Garcia A, Alonso MM. The Oncolytic Virus Delta-24 RGD in Combination with an Agonistic CD40 MAB Induces a Durable and Synergetic Anti-Tumor Immune Effect in DIPG Preclinical Models. Neuro Oncol 23(Supplement_1):i26, i27, 2021. e-Pub 2021.
112. Laspidea V, Gupta S, Puigdelloses M, Labiano S, Ausejo-Mauleon I, de la Nava D, Becher OJ, Gumin J, Fueyo J, Gomez-Manzano C, Alonso MM. Delta-24 RGD Expressing Positive Immune Modulators Show Anti-DIPG Effect and Increase Tumor Immune Infiltration. Neuro Oncol 23(Supplement_1):i28, 2021. e-Pub 2021.
113. Gomez-Manzano C, Melendez C, Nguyen T, Ossimetha A, Jiang H, Fueyo J, Godoy-Vitorino F. Gut Microbiome changes are associated with the efficacy of Delta-24-RGDOX viroimmunotherapy against malignant glioma. Cancer Res 81(Supplement_13):927, 2021. e-Pub 2021.
114. Sohoni S, Nguyen T, Shin DH, Fan X, Jiang H, Gupta S, Ossimetha A, Yi Y, Bartholomeusz C, Alonso M, Fueyo J, Gomez-Manzano C. Targeting the immunosuppressive microenvironment of metastatic breast cancer with viroimmunotherapy. Cancer Res 81(Supplement_13):1786, 2021. e-Pub 2021.
115. Ossimetha A, Nguyen T, Melendez N, Fan X, Alonso MM, Fueyo J, Godoy-Vitorino F, Gomez-Manzano C. Armed oncolytic adenovirus expressing the positive immune checkpoint OX40L for gastric cancer therapy. Cancer Res 81(Supplement_13):1748, 2021. e-Pub 2021.
116. Shin DH, Nguyen TT, Jiang H, Fan X, Yi Y, Sohoni S, Gupta S, Ossimetha A, Gomez-Manzano C, Fueyo J. Evasion of neutralizing antibodies andenhanced anti-tumor effectsof hexon-modified Delta-24-RGD oncolytic adenovirus. Cancer Res 81(Supplement_13):1912, 2021. e-Pub 2021.
117. Jiang H, Nguyen T, Shin DH, Sohoni S, Gupta S, Yi Y, Fan X, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus Delta-24-RGDOX collaborates with adoptive T cell therapy to sustain systemic anti-tumor immunity. Cancer Res 81(Supplement_13):1579, 2021. e-Pub 2021.
118. Nguyen T, Shin DH, Jiang H, Wainwright DA, Sohoni S, Gupta S, Ossimetha A, Lang F, Alonso MM, Gomez-Manzano C, Fueyo J. Inhibition of the IDO-Kyn-AhR cascade optimizes virotherapy in glioblastoma and depends on CD4 T-cell activation. Cancer Res 81(Supplement_13):1785, 2021. e-Pub 2021.
119. Gupta S, Laspidea V, Fueyo J, Becher O, Nguyen T, Shin DH, Jiang H, Sohoni S, Fan X, Yi Y, Gumin J, Lang F, Gomez-Manzano C, Alonso MM. Armed Oncolytic virus for treatment of pediatric diffuse intrinsic pontine glioma. Cancer Res 81(Supplement_13):3053, 2021. e-Pub 2021.
120. Melendez-Vazquez NM, Nguyen T, Ossimetha A, Sahoni SS, Fueyo J, Gomez-Manzano C, Godoy-Vitorino F. Bacterial Gut biota changes are associated with the efficacy of Delta-24-RGDOX viroimmunotherapy against malignant glioma. Puerto Rico Society of Microbiologist 63rd Annual Meeting: “Thriving into new horizons: Hopeful rethinking in microbial sciences”, 2021. e-Pub 2021.
121. Alonso MM, Iñigo-Marco I, Garcia-Moure M, Gonzalez-Huarriz M, Jones C, McCkay A, Hulleman E, Van der Lugt J, De Andrea C, Villalba M, Hernandez R, Hervas S, Tamayo I, Frederick Lang F, Gomez-Manzano C, Fueyo J, Diez-Valle R, Gallego-Perez J, Tejada S. Oncolytic virus for DIPG: the clinical experience with DNX-2401. Neuro Oncol 22(suppl 2):ii38, 2020. e-Pub 2020.
122. Nguyen T, Shin DH, Jiang H, Wainwright D, Sohoni S, Gupta S, Ossimetha A, Lang F, Alonso MM, Fueyo J, Gomez-Manzano C. Delta-24-RGDOX activation of the IDO-Kyn-AhR cascade in glioblastoma: old targets for a new therapy. Neuro Oncol 22(suppl 2):ii97, 2020. e-Pub 2020.
123. Garcia-Moure M, González-Huarriz M, Laspidea V, Marrodán L, Gomez-Manzano C, Fueyo J, Patiño-Garcia A, Alonso MM. Characterization of the oncolytic adenovirus Delta-24-RGD as therapeutic agent for the treatment of the pediatric embryonal brain tumors AT/RT and CNS-PNET. Neuro Oncol 22(suppl 2):ii100, 2020. e-Pub 2020.
124. Puigdelloses M, Laspidea V, Garcia-Moure M, De la Nava D, Hambardzumyan D, Chen Z, Labiano S, Fueyo J, Gomez-Manzano C, Gallego-Perez J, Alonso MM. The combination of Delta-24-ACT with an immune checkpoint inhibitor results in anti-glioma effect and immune memory. Neuro Oncol 22(suppl 2):ii109, 2020. e-Pub 2020.
125. Shin DH, Nguyen T, Jiang H, Sohoni S, Gupta S, Ossimetha A, Alonso M, Gomez-Manzano C, Fueyo J. Hexon swapping mitigates anti-viralimmune responseduring brain tumor virotherapy. Neuro Oncol 22(suppl 2):ii95, 2020. e-Pub 2020.
126. Laspidea V, Puigdelloses M, Martinez-Velez N, Garcia-Moure M, Labiano S, Ausejo I, Patiño-García A, Becher OJ, Jiang H, Gupta S, Fueyo J, Gomez-Manzano C, Alonso MM. Oncolytic adenovirus Delta-24-RGD engineered to express 4-1BBl as a therapeutic approach for DIPG. Neuro Oncol 22(suppl 2):ii107, 2020. e-Pub 2020.
127. Phillips L, Gumin J, Li S, Daou M, Ledbetter D, Hossain A, Parker Kerrigan B, Gomez-Manzano C, Fueyo J, Lang F. A novel adenoviral-permissive, immunocompetent hamster glioma model to evaluate oncolytic adenoviral therapy. Neuro Oncol 22(suppl 2):ii231, 2020. e-Pub 2020.
128. Ossimetha A, Nguyen T, Juan Fueyo J, Godoy Vitorino F, Gomez-Manzano. Anti-cancer effect of viroimmunotherapy to treat gastric cancer. 2020 Annual Medical Education Conference (AMEC) | The Student National Medical Association (SNMA) Wilbert C. Jordan Research Forum, 2020. e-Pub 2020.
129. Laspidea V, Puigdelloses M, Iñigo-Marco I, Garcia-Moure M, Ausejo I, Gallego J, Fueyo J, Gomez-Manzano C, Alonso MM. Oncolytic virus expressing a positive immune checkpoint modulator as a therapeutic approach for DIPG. Neuro Oncol 21(suppl_6):vi122, 2019. e-Pub 2019.
130. Garcia-Moure M, González Huarriz M, Laspidea V, Marrodán L, Gomez-Manzano C, Fueyo J, Patiño-García A, Alonso MM. Delta-24-RGD oncolytic adenovirus mediates anti-tumor effect in localized and disseminated AT/RT murine models. Neuro Oncol 21(suppl_6):vi192, 2019. e-Pub 2019.
131. Rivera-Molina Y, Fueyo J, Jiang H, Nguyen T, Shin DH, Youssef G, Fan X, Gumin J, Alonso MM, Phadnis S, Lang F, Gomez-Manzano C. Activating the immunity within the tumor using viroimmunotherapy: Delta-24-RGD oncolytic adenovirus armed with the immunopositive regulator GITRL. Neuro Oncol 21(suppl_6):vi87, 2019. e-Pub 2019.
132. Iñigo-Marco I, Díez-Valle R, Garcia-Moure M, Patiño-García A, González Huarriz M, Jones C, Gomez-Manzano C, Fueyo J, Alonso MM, Tejada S. Phase I clinical trial with oncolytic virus DNX-2401 for DIPGs. Neuro Oncol 21(suppl_6):vi283-vi284, 2019. e-Pub 2019.
133. Jiang H, Shin DH, Nguyen T, Alonso MM, Lang F, Gomez-Manzano C, Fueyo J. Treatment with Delta-24-RGDOX of subcutaneous tumors results in abscopal effect eradicating intracranial melanomas. Neuro Oncol 21(suppl_6):vi84, 2019. e-Pub 2019.
134. Nguyen N, Shin DH, Jiang H, Lang F, Gomez-Manzano C, Fueyo J. Combined IDO inhibitor and OX40L-armed-oncolytic-adenovirus therapy improves survival in murine glioblastoma. Cancer Immunol Res 8(Supplement_3):A30, 2019. e-Pub 2019.
135. Jiang H, Shin DH, Nguyen T, Lang FF, Gomez-Manzano C, Fueyo J. Systemic immunity against disseminated subcutaneous and intracranial melanomas induced by oncolytic adenovirus Delta-24-RGDOX. JITC 7(suppl 1):283, 2019. e-Pub 2019.
136. Laspidea V, Puigdelloses M, Garcia-Moure M, Iñigo Marco I, Gallego J, Fueyo J, Gomez-Manzano C, Alonso MM. Delta-24-ACT oncolytic adenovirus as a therapeutic approach for DIPG. Neuro Oncol, 2019. e-Pub 2019.
137. Alonso MM, Iñigo I, Gonzalez-Huarriz M, Dominguez P, Patiño A, Jones C, Gomez-Manzano C, Fueyo J, Diez-Valle R, Tejada S. Phase I clinical trial with oncolytic virus DNX-2401 for DIPGs. Neuro Oncol, 2019. e-Pub 2019.
138. Laspidea V, Puigdelloses M, Moure M, Marco I, Gallego J, Fueyo J, Gomez-Manzano C, Alonso MM. Delta-24-ACT oncolytic adenovirus as a therapeutic approach for DIPG. 14th European Association of Neuro-Oncology (EANO) 2019, 2019. e-Pub 2019.
139. Alonso MM, Inigo I, Gonzalez-Huarriz M, Dominguez P, Patino A, Jones C, Gomez-Manzano C, Fueyo J, Diez-Valle R, Tejada S. Phase I clinical trial with oncolytic virus DNX-2401 for DIPGs. 14th European Association of Neuro-Oncology (EANO) 2019, 2019. e-Pub 2019.
140. Martinez-Velez N, Garcia-Moure M, Laspidea V, Becher O, Fueyo J, Gomez-Manzano C, Patiño A, Diez-Valle R, Tejada-Solis S, Alonso M. Translation of DNX-2401 from the bench to the clinic for pediatric high grade gliomas including diffuse intrinsic pontine gliomas. Neuro Oncol 21(suppl_2):ii68-ii69, 2019. e-Pub 2019.
141. Laspidea V, Varela-Guruceaga M, García-Moure M, Gonzalez-Huarriz M, Fueyo J, Gomez-Manzano C, Alonso MM. Immune oncolytic adenovirus for DIPG treatment. Neuro Oncol 21(suppl_2):ii119, 2019. e-Pub 2019.
142. Shin DH, Jiang H, Nguyen T, Youssef G, Fan X, Yi Y, Gomez-Manzano C, Fueyo J. Glioblastoma disguised: combined therapy using CD19 expressing oncolytic adenovirus and CD19-targeted CAR T-cells. Cancer Res, 2019. e-Pub 2019.
143. Jiang H, Shin DH, Carrillo C, Henry V, Fan X, Nguyen T, Rivera-Molina Y, Lang FF, Gomez-Manzano C, Fueyo J. Systemic anti-melanoma immunity induced by oncolytic adenovirus Delta-24-RGDOX. Proceedings of the AACR Special Conference: Melanoma: From Biology to Target. e-Pub 2019.
144. Jiang H, Shin DH, Carrillo C, Henry V, Fan X, Nguyen TT, Rivera-Molina Y, Lang FF, Gomez-Manzano C, Fueyo J. Localized treatment with oncolytic adenovirus Delta-24-RGDOX elicits efficacious abscopal immunity against disseminated melanomas. JITC, 2018. e-Pub 2018.
145. Jiang H, Shin DH, Carrillo C, Henry V, Fan X, Nguyen TT, Rivera-Molina Y, Lang F, Gomez-Manzano C, Fueyo J. Localized treatment with oncolytic adenovirus Delta-24-RGDOX elicits efficacious abscopal immunity against disseminated melanomas. The Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting 2018 6(Suppl 1):327-328, 2018. e-Pub 2018.
146. Nguyen TT, Rivera-Molina Y, Puerta-Martinez FW, Fan X, Carillo CC, Henry VK, Jiang H, Lang FF, Gomez-Manzano C, Fueyo J. Forced expression of OX40L and inhibition of IDO within the glioblastoma tumor microenvironment creates a potent anti-tumor immune response. JITC, 2018. e-Pub 2018.
147. Nguyen TT, Rivera-Molina Y, Puerta-Martinez FW, Fan X, Henry V, Jiang H, Lang F, Fueyo J, Gomez-Manzano C. Inflammatory reprogramming of gliomas using Delta-24-RGDOX and imnunometabolic adjuvants. Neuro-Oncology (23rd Annual Scientific Meeting and Education Day of The Society for Neuro-Oncology; Nov 15-18, New Orleans, LA) 20(suppl_6):vi90-vi91, 2018. e-Pub 2018.
148. Jiang H, Nguyen T, Shin DH, Fan X, Gumin J, Bernatchez C, Lang F, Gomez-Manzano C, Fueyo J. In situ autovaccination mediated by oncolytic adenovirus Delta-24-RGDOX induces efficacious immunity against metastatic melanoma. Neuro-Oncology (23rd Annual Scientific Meeting and Education Day of The Society for Neuro-Oncology; Nov 15-18, New Orleans, LA) 20(suppl_6):vi91, 2018. e-Pub 2018.
149. Phillips L, Li S, Gumin J, Ledbetter D, Hossain A, Kerrigan B, Gomez-Manzano C, Fueyo J, Lang F. A novel adenoviral-permissive, immunocompetent hamster model to evaluate oncolytic adenoviral therapy for glioblastoma. Neuro-Oncology (23rd Annual Scientific Meeting and Education Day of The Society for Neuro-Oncology; Nov 15-18, New Orleans, LA) 20(suppl_6):vi272, 2018. e-Pub 2018.
150. Nguyen TT, Rivera-Molina Y, Puerta-Martinez FW, Fan X, Carrillo CC, Henry VK, Jiang H, Lang F, Gomez-Manzano C, Fueyo J. Forced expression of OX40L and inhibition of IDO within the glioblastoma tumor microenvironment creates a potent anti-tumor immune response. The Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting 2021 6(Suppl 1):190, 2018. e-Pub 2018.
151. Martinez-Velez N, Marigil M, Aristu J, Ramos L, Pastor F, Patiño-Garcia A, Garcia-Moure M, Fueyo J, Gomez-Manzano C, Alonso MM. Aptamers, antibodies and radiotherapy for the treatment of DIPG. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Chicago, IL, April 14-18, 2018) 78(13 suppl), 2018. e-Pub 2018.
152. Puerta Martinez F, Yisel A Rivera Y, Nguyen T, Fan X, Rehnuma S, Hossain MB, Jiang H, Bartholomeusz C, Lang FF, Fueyo J, Gomez-Manzano C. Partial reversion of the tumor immunosuppressed environment by oncolytic adenoviruses armed with positive stimulators of the immune synapis in breast cancer. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Chicago, IL, April 14-18, 2018) 78(13 suppl), 2018. e-Pub 2018.
153. Hossain MB, Shifat R, Rivera-Molina Y, Francisco Puerta Martinez F, Jiang H, Kim DK, Johnson DG, Bedford MT, M-C H, Sulman EP, Lang F, Sawaya R, Fueyo J, Gomez-Manzano C. Histone tyrosine phosphorylation determines glioblastoma cell survival. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Chicago, IL, April 14-18, 2018) 78(13 suppl), 2018. e-Pub 2018.
154. Fueyo J, Gomez-Manzano C, Villalobos P, Rodriguez-Canales J, Mino B, Wistuba I, Hess K, Alonso M, Tejada S, Diez-Valle R, Ewald B, Tufaro F, Lang F. Delta-24-RGD oncolytic adenovirus treatment downmodulates the key regulator of T-cell exhaustion TIM3 in malignant gliomas. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Washington, DC, April 1-5, 2017) 77(13 suppl):LB235, 2018. e-Pub 2018.
155. Martínez-Vélez N, Marigil M, García-Moure M, Aristu J, Ramos L, Becher O, Pastor F, Patiño A, Gomez-Manzano C, Juan Fueyo J, Díaz-Valle R, Tejada S, Alonso MM. Combinatorial advanced therapies for the treatment of DIPGs: Radiotherapy plus antibodies and aptamers. Proceedings of the Am. Assoc. Cancer Res. (Immunobiology of Primary and Metastatic CNS Cancer: Multidisciplinary Science to Advance Cancer Immunotherapy; Special AACR Meeting; February 12-15, 2018, San Diego, CA), 2018. e-Pub 2018.
156. Jiang H, Dong A, Carrillo C, Henry V, Fan X, Rivera-Molina Y, Puerta-Martinez F, Nguyen T, Clise-Dwyer K, Lang F, Gomez-Manzano C, Fueyo J. Efficacious anti-melanoma immunity induced by OX40 ligand-expressing oncolytic adenovirus Delta-24-RGDOX. 32nd Annual Meeting of the Society for Immunotherapy of Cancer (National Harbor, MD; Nov. 8-12, 2017), 2017. e-Pub 2017.
157. Garcia-Moure M, Martínez-Vélez N, González-Huarriz M, Puigdelloses M, Idoate MA, Diez Valle R, Tejada S, Gomez-Manzano C, Fueyo J, Patiño Garcia AP, Alonso MM. The Oncolytic Adenovirus Delta-24-RGD Mediates an Efficient Antitumor Response in vivo in Supratentorial Primitive Neuroectodermal Tumors. Neuro-Oncol (22nd Annual Scientific Meeting and Education Day of The Society for Neuro-Oncology; Nov 16-19, San Francisco, CA) 19(suppl.6):vi192, 2017. e-Pub 2017.
158. Hossain M, Shifat R, Rivera-Molina Y, PuertaMartinez F, Jiang H, Kim D, Johnson D, Bedford M, Sulman E, Lang F, Fueyo J, Gomez-Manzano C. TIE2-mediated epigenetic modifications regulate radioresistance of glioblastoma. Neuro-Oncol (22nd Annual Scientific Meeting and Education Day of The Society for Neuro-Oncology; Nov 16-19, San Francisco, CA) 19(suppl.6):vi96, 2017. e-Pub 2017.
159. Fueyo J, Gomez-Manzano C, Villalobos P, Rodriguez-Canales J, Wistuba I, Hess K, Alonso M, Tejada S, Diez Valle R, Ewald B, Tufaro F, Lang F. Immunomarkers in the DNX-2401 (Delta-24-RGD) oncolytic virus phase I clinical trial. Neuro-Oncol (22nd Annual Scientific Meeting and Education Day of The Society for Neuro-Oncology; Nov 16-19, San Francisco, CA) 19(suppl. 6):vi27, 2017. e-Pub 2017.
160. Belayat Hossain M, Shifat R, Li J, Rivera-Mokina Y, Puerta Martinez F, Johnson DG, Bedford MT, M-C H, Sulman EP, Lang F, Sawaya R, Fueyo J, Gomez-Manzano C. TIE2-mediated epigenetic marks regulate therapeutic resistance of glioblastoma. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Washington DC, April 1-5, 2017) 77(13 suppl):5854, 2017. e-Pub 2017.
161. Alonso MM, Garcia-Moure M, Gonzalez-Huarriz M, Marigil M, Hernandez-Alcoceba R, Buñales M, Hervas S, Gallego J, Gomez-Manzano C, Fueyo J, Lang J, Peterkin J, Diez-Valle, Tejada S. Oncolytic virus DNX-2401 with a short course of temozolomide for glioblastoma at first recurrence: clinical data and prognostic biomarkers. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Washington, DC, April 1-5, 2017) 77(13 suppl):CT027, 2017. e-Pub 2017.
162. Rivera-Molina Y, Puerta Martinez F, Nguyen T, Jiang H, Fan X, Shifat R, Hossain MB, Henry VK, Carrillo CC, Gomez-Manzano, Fueyo J. Forced expression of GITRL in cancer cells enhances adenovirus-mediated in situ vaccination. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Washington DC, April 1-5, 2017) 77(13 suppl):4565, 2017. e-Pub 2017.
163. Garcia-Moure M, Martínez-Vélez N, Gonzalez-Húarriz M, Puigdelloses M, Patiño-Garcia A, Idoate MA, Díez-Valle R, Tejada S, Gomez-Manzano C, Fueyo J, Alonso. Treatment of PNETs with the oncolytic adenovirus Delta-24-RGD results in antitumor effect. Neuro-Oncology (4th Biennial Conference on Pediatric Neuro-Oncology Basic and Translational Research, June 15-16, 2017, New York City) 19(suppl. 4):iv42, 2017. e-Pub 2017.
164. Garcia Moure M, Martínez-Vélez N, Xipell E, González-Huarriz M, Patiño A, Becher OJ, Gomez-Manzano C, Fueyo J, Alonso MM. Therapeutic potential of Delta24-ACT, a novel immunostimulatory oncolytic adenovirus, for the treatment of pediatric solid tumors: Initial study in pHGG, DIPG and osteosarcoma. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Washington DC, April 1-5, 2017) 77(13 suppl):704, 2017. e-Pub 2017.
165. Marini F, Chifman J, Tooze J, Gomez-Manzano C, Bussard KM. Osteoblasts are educated into a tumor-associated stromal cell by disseminated breast cancer cells and mediate breast cancer cell proliferation in the bone microenvironment. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Washington DC, April 1-5, 2017) 77(13 suppl):5890, 2017. e-Pub 2017.
166. Jiang H, Dong A, Rivera-Molina Y, Clise-Dwyer K, Fan X, Puerta Martinez F, Nguyen T, Henry V, Carrillo C, Gomez-Manzano C, Fueyo J. Cancer-killing viruses combined with tumor-targeting immune checkpoint modulation elicits an in situ vaccination effect and expansion of tumor-specific T cells responsible for efficacious systemic anti-cancer activity. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Washington DC, April 1-5, 2017) 77(13 suppl):3680, 2017. e-Pub 2017.
167. Puerta Martinez F, Rivera Y, Nguyen T, Fan X, Henderson JM, Rehnuma S, Hossain MB, Jiang H, Fueyo J, Gomez Manzano C. Oncolytic adenoviruses expressing OX40L or GITRL immune modulators show antitumor effect on immune-competent mouse breast cancer models. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Washington DC, April 1-5, 2017) 77(13 suppl):3668, 2017. e-Pub 2017.
168. Lang FF, Tran ND, Puduvalli VK, Elder JB, Fink KL, Conrad CA, Yung WKA, Penas-Prado M, Gomez-Manzano C, Peterkin J, Fueyo J. Phase 1b open-label randomized study of the oncolytic adenovirus DNX-2401 administered with or without interferon gamma for recurrent glioblastoma. Journal of Clinical Oncology (ASCO Annual Meeting, June 2-6 2017, Chicago, IL) 35(15_suppl):2002, 2017. e-Pub 2017.
169. Martinez-Velez N, Marigil Sanchez M, Dominguez P, Aristu JJ, Fueyo J, Gomez-Manzano C, Junier MP, Chneiweiss H, El-harb E, Diez Valle R, Tejada S, Alonso MM. Looking for a cure:Delta-24-RGD and radiotherapy for DIPG treatment. Neuro-Oncology (21st Annual Meeting and Education Day, Scottsdale, Arizona, November 17-20, 2016) 18(suppl. 6):vi61, 2016. e-Pub 2016.
170. Puerta F, Rivera-Molina Y, Jiang H, Dong A, Fan X, Gomez-Manzano C, Fueyo J. Targeting gliomas and metastatic cancer with oncolytic adenoviruses expressing T-cell activators. DNA Tumor Virus Meeting, McGill Cancer Research Center, Montreal, Quebec, Canada, July 18-23, 2016, 2016. e-Pub 2016.
171. Gomez-Manzano, Hossain MB, Shifat R, Johnson D, Bedford M, M-C H, Sulman E, Lang F, Sawaya R, Yung WKA, Fueyo J. Tie2 mediates DNA repair in brain tumor stem cells vis histone phosphorylation and ABL1 recruiting. The 21st International Conference on Brain Tumor Research and Therapy (Okinawa, Japan, April 9-13, 2016), 2016. e-Pub 2016.
172. Rivera-Molina Y, Hong Jiang H, Puerta Martinez F, Nguyen T, Fan X, Gomez-Manzano C, Fueyo J. Armed-oncolytic virus Delta-24-GREAT expressing GITRL induces potent anti-glioma effect and specific anti-tumor memory. Tumor Immunology and Immunotherapy, American Association for Cancer Research, Boston, MA, October 20-23, 2016, 2016. e-Pub 2016.
173. Jiang H, Clise-Dwyer K, Bover L, Lang FF, Gomez-Manzano C, Fueyo J. Potentiation of anti-glioma immunity induced by oncolytic adenovirus Delta-24-RGD through viral expression of immune co-stimulator OX40 ligand. J ImmunoTher Cancer. (Society for Immunotherapy of Cancer 30th Annual Meeting, National Harbor, MD; November 4-8, 2015) 3(suppl 2):337, 2015. e-Pub 2015.
174. Hossain MB, Shifat R, Johnson DG, Bedford MT, M-C H, Gabrusiewicz K, Gumin J, Ezhilarasan R, Sulman EP, Lang F, Tyler J, Sawaya R, Yung WKA, Fueyo J, Gomez-Manzano C. Tyrosine kinase receptor Tie2 regulates DNA repair through the proto-oncogene Abl1 in brain tumor stem cells. Neuro-Oncology (20th Annual Meeting of the Society for Neuro-Oncology; San Antonio, TX, Nov 19-22, 2015) 17(suppl. 5):v197, 2015. e-Pub 2015.
175. Jiang J, Gomez-Manzano C, Lang F, Tufaro F, Yung WKA, Sawaya R, Fueyo J. Combination of Delta-24-RGDOX and anti-PDL1 antibodies induces anti-tumor effect and antiglioma immune memory. Neuro-Oncology (20th Annual Meeting of the Society for Neuro-Oncology; San Antonio, TX, Nov 19-22, 2015) 17(suppl.5):v114-115, 2015. e-Pub 2015.
176. Moreno M, Pineda E, Martinez J, Bejarano L, Balasubramaniyan V, Ezhi, arasan R, Kallarackal N, S-H K, Pare L, Tortosa A, Gomez-Manzano C, Graus F, Sulman E, Piao X, Nakano I, Prat A, Bhat K, de la Iglesia N. Inhibition of the neural stem cell/oligodendrocyte progenitor factor GPR56 promotes the proneural to mesenchymal transition and radioresistance in glioblastoma. Neuro-Oncology (20th Annual Meeting of the Society for Neuro-Oncology; San Antonio, TX, Nov 19-22, 2015) 17(suppl.5):v209-v210, 2015. e-Pub 2015.
177. Jiang H, Gomez-Manzano C, Clise-Dwyre K, Bover L Vence LM, Lang FF, Conrad CA, Toniatti C, Tufaro F, Fueyo J. Delta-24-RGDOX: Expressing OX40L in gliomas using replication competent oncolytic adenoviruses induces anti-tumor effect and antiglioma immune memory. CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, New York, NY (September 16-19, 2015), 2015. e-Pub 2015.
178. Jiang H, Clise-Dwyer K, Bover L, Lang FF, Yung WKA, Gomez-Manzano C, Fueyo J. Delta-24-RGDOX: an oncolytic adenovirus enhances anti-glioma immunity through expressing the immune checkpoint co-stimulator OX40 ligand. 9th International Conference on Oncolytic Virus Therapeutics; Harvard Medical School, June 13-16, 2015, Boston, MA, 2015. e-Pub 2015.
179. Klein SR, Jiang H, Gomez-Manzano C, Fueyo J. Role of JNK in the regulation of autophagy in adenovirus-infected cancer cells: clinical implications. 2nd. Symposium Autophagy- Across Biology and Medicine; April 24, 2015; Houston, TX, 2015. e-Pub 2015.
180. Jiang H, Alonso M, Hossain MB, Gomez-Manzano C, Fueyo J. Delta-24-RGDOX: Targeting OX40/OX40L in brain tumors using oncolytic adenoviruses. Cell Symposia: Cancer, Inflammation, and Immunity; June 14-16, 2015; Sitges, Spain, 2015. e-Pub 2015.
181. Gabrusiewicz K, Cortes-Santiago N, Hossain MB, Fan X, Kaminska B, Marini, Fueyo J, Gomez- Manzano C. CSFR1-guided macrophage ablation preferentially targets M2 populations and jeopardizes glioma growth. Cell Symposia: Cancer, Inflammation, and Immunity; June 14-16, 2015; Sitges, Spain, 2015. e-Pub 2015.
182. Jiang H, Fan X, Clise-Dwyer K, Bover L, Gumin J, Ruisaard KE, Mukheef FJ, Lang FF, Gomez-Manzano C, Fueyo J. Delta-24-RGDOX: making cancer more “visible” to the immune system. Proceedings of the 2015 Annual Meeting of the American Association for Cancer Research (AACR); 2015 Apr 18-22; Philadelphia, PA, 2015. e-Pub 2015.
183. Hossain MB, Shifat R, Johnson DG, Bedford MT, M-C H, Cortes-Santiago N, Gabrusiewicz K, Gumin J, Ezhilarasan R, Sulman EP, Lang F, Sawaya R, Yung WKA, Fueyo J, Gomez-Manzano C. ABL1 is required for Tie2-mediated DNA repair in brain tumor stem cells. Proceedings of the 2015 Annual Meeting of the American Association for Cancer Research (AACR); 2014 Apr 18-22; Philadelphia, PA, 2015. e-Pub 2015.
184. Cortes-Santiago N, Hossain M, Gabrusiewick K, Fan X, Jiang H, Shifat R, Alonso MM, Fueyo J, Gomez-Manzano C. Counterattacking the force behind glioma invasion. Neuro-Oncology. 19th Annual Scientific Meeting of the Society for Neuro-Oncology, November 13-16, 2014, Miami, FL 16(suppl.5):v120, 2014. e-Pub 2014.
185. Xipell E, Martinez-Velez N, Vera-CAno B, Idoate MA, Gracia Gazon A, Acanda AM, Fueyo J, Gomez-Manzano C, Alonso MM. ER-Stress inducing drugs sensitizes GBM to temozolomide of MGMT and induction of regulated necrosis. Neuro-Oncol (19th Annual Scientific Meeting of the Society for Neuro-Oncology; Nov 13-16, 2014; Miami, FL) 16(suppl. 5):v93, 2014. e-Pub 2014.
186. Lang FF, Conrad C, Gomez-Manzano C, Tufaro F, Yung WKA, Sawaya R, Weinberg J, Prabhu S, Fuller G, Aldape K, Fueyo J. Phase I Clinical Trial of oncolytic Delta-24-RGD (DNX2401) with Biological Endpoints: Implications for Viro-Immunotherapy. Neuro-Oncol, 19th Annual Scientific Meeting of the Society for Neuro-Oncology; Nov 13-16, 2014, Miami, FL 16(suppl. 5):v163, 2014. e-Pub 2014.
187. Jiang H, Lang F, Fan X, Gumin J, Bover L, Clise-Dwyer K, Toniatti C, Ruisard K, Conrad C, Vence L, Gomez-Manzano C, Fueyo J. Delta-24-RGDOX: Targeting co-stimulatory immune checkpoints proteins with oncolytic adenoviruses. Neuro-Oncology. 19th Annual Scientific Meeting of the Society for Neuro-Oncology, November 13-16, 2014, Miami, FL 16(suppl. 5):v112, 2014. e-Pub 2014.
188. Piya S, Jiang H, Klein SR, Yung WKA, Sawaya R, Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses modulate autophagy in cancer cells via sumoylation of LC3. Proceedings of the 105st Annual Meeting of the American Association for Cancer Research (AACR); 2014 Apr 5-9; San Diego, CA, 2014. e-Pub 2014.
189. Jiang H, Clise-Dwyer K, Fan X, GuminJ, Mukheef F, Bover L, Toniatti C, Ruisard K, Vence L, Yung WKA, Gomez-Manzano C, Fueyo J. Enhancement of anti-tumor immunity induced by OX40 ligand-expressing oncolytic adenovirus Delta-24-RGDOX. NIH/NCI Cancer Immunology and Immunotherapy: Delivering the Promise, October 9-10, 2014, Bethesda, MD, 2014. e-Pub 2014.
190. Hossain MB, Cortes-Santiago N, Fan X, Gabrusiewicz K, Gumin J, Sulman EP, Lang F, Sawaya R, Yung WKA, Fueyo J, Gomez-Manzano C. Caveolin-mediated Tie2 nuclear translocation results in enhanced NHEJ repair and glioma radioresistance. Proceedings of the 105st Annual Meeting of the American Association for Cancer Research (AACR); 2014 Apr 5-9; San Diego, CA, 2014. e-Pub 2014.
191. Gabrusiewicz K, Cortes-Santiago N, Fan X, Hossain MB, Kaminska B, Heimberger A, Rao G, Marini F, Fueyo J, Gomez-Manzano C. Modeling tumor microenvironment in vivo: impact of conditional macrophage ablation in glioma progression. Neuro-Oncology (4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 2013 Scientific Meeting and Education Day of the Society for Neuro-Oncology, November 21-24, 2013, San Francisco, CA) 15(Supplement 3):iii236, 2013. e-Pub 2013.
192. Jiang H, Klein S, Piya S, Vence L, Yung WKA, Sawaya R, Heimberger A, Conrad C, Lang F, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus Delta-24-RGD infection activates T-cell immune response against glioma cells. Neuro-Oncology (4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 2013 Scientific Meeting and Education Day of the Society for Neuro-Oncology, November 21-24, 2013, San Francisco, CA) 15(Supplement 3):iii63-iii64, 2013. e-Pub 2013.
193. Fueyo J, Gomez-Manzano C, Conrad C, Yung WKA, Aldape K, Sawaya R, Lang F. Significance of cancer autoantibodies in patents with malignant gliomas treated with Delta-24-RGD. Neurology (The 65Th Annual Meeting of the American Academy of Neurology; March 16-23, 2013, San Diego, CA) 80, 2013. e-Pub 2013.
194. Cortes-Santiago N, Gabrusiewicz K, Liu D, Hossain MB, Conrad C, Fueyo, Gomez-Manzano C. Understanding the mechanism underlying recurrence of malignant gliomas after anti-angiogenesis treatment. AACR Special Conference; Proceedings on Tumor Invasion and Metastasis (January 20-23, 2013, San Diego, CA), 2013. e-Pub 2013.
195. Klein SR, Jiang H, Piya S, White EJ, Fan X, Lu Z, Yung WKA, Gomez-Manzano C, Fueyo J. C-Jun N-terminal kinases regulate adenovirus-induced autophagy: the implications for cancer immunotherapy using oncolytic adenoviruses. AACR Special Meeting: Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances; December 2-5, 2012; Miami, FL, 2012. e-Pub 2012.
196. Cortes-Santiago N, Gabrusiewicz K, Liu D, Hossain MB, Gumin J, Fan X, Conrad C, Aldape K, Gilbert M, RAghunathan A, Yung WKA, Fueyo J, Gomez-Manzano C. Insights on the role of microenvironment in the recurrence of malignant gliomas to anti-VEGF therapy: Opportunites for new combined therapies. Neuro-Oncology (17th Annual Scientific Meeting of the Society for Neuro-Oncology & AANS/CNS Section on Tumors, November 15-18, 2012, Washington, DC) 14(11), 2012. e-Pub 2012.
197. Hossain MB, Cortes-Santiago N, Gururaj A, Thomas J, Gabrusiewicz K, Gumin J, Xipell E, Lang F, Fueyo, Gomez-Manzano C. Unexpected nuclear sub localization of the tyrosine kinase receptor Tie2 induces radioresistance of malignant gliomas. Neuro-Oncology (17th Annual Scientific Meeting of the Society for Neuro-Oncology & AANS/CNS Section on Tumors, November 15-18, 2012, Washington, DC) 14(11), 2012. e-Pub 2012.
198. Xipell E, Jauregui P, Gonzalez M, Tejada-Solis S, Diez-Valle R, Tuno T, Zazpe I, Mora J, Montero A, Gomez-Manzano C, Fueyo J, Alonso M. Delta-24-RGD in combination with salinomycin for the treatment of high-grade pediatric gliomas. Neuro-Oncology (17th Annual Scientific Meeting of the Society for Neuro-Oncology & AANS/CNS Section on Tumors, November 15-18, 2012, Washington, DC) 14:vi117, 2012. e-Pub 2012.
199. Fueyo J, Gomez-Manzano C, Conrad C, Heimberger A, Vence L, Aldape K, Yung WKA, Sawaya R, Fuller G, Lang F. Phase I clinical trial in patients with recurrent gliomas: Delta-24-RGD oncolytic adenovirus induces an antiglioma immune-response. Journal of Neurology (Twenty-second Meeting of the European Neurological Society 9-12 June, 2012, Prague, Czech Republic) 259:S46, 2012. e-Pub 2012.
200. Gabrusiewicz KR, Fueyo J, Liu D, Cortes-Santiago N, Hossain MB, Conrad CA, Gilbert M, Yung WKA, Fuller G, Gomez-Manzano C. New therapeutic targets for malignant gliomas: role of Tie2-expressing monocytes in the failure of antiangiogenesis therapies. Journal of Neurology (Twenty-second Meeting of the European Neurological Society 9-12 June, 2012, Prague, Czech Republic) 256:S45, 2012. e-Pub 2012.
201. Hossain MB, Gururaj A, Cortes-Santiago N, Gabrusiewicz K, Fueyo J, Gomez-Manzano C. Nuclear trafficking of Tie2 is associated with radioresistance of gliomas. Cancer Research (Proceedings: AACR 103rd Annual Meeting 2012---March 31-April 4; Chicago, IL) 72(8), 2012. e-Pub 2012.
202. Gabrusiewicz KR, Liu D, Cortes-Santiago N, Hossain MB, Piya S, Conrad C, Marini FC, Fueyo J, Gomez-Manzano C. Recruitment of Tie2-expressing monocytes is associated with the heightened invasive phenotype of gliomas after antiangiogenic therapies. Cancer Research (Proceedings: AACR 103rd Annual Meeting 2012---March 31-April 4; Chicago, IL) 72(8), 2012. e-Pub 2012.
203. Fueyo J, Conrad C, Gomez-Manzano C, Heimberger A, Vence L, Aldape K, Yung WKA, Sawaya R, Fuller G, Lang F. Analyses of anti-cancer testis antigen antibodies in glioma patients treated with Delta-24 oncolytic adenovirus. Cancer Research (Proceedings: AACR 103rd Annual Meeting 2012---March 31-April 4; Chicago, IL) 72(8), 2012. e-Pub 2012.
204. Piya S, White E, Klein S, Jiang H, Lang F, Yung WKA, Gomez-Manzano C, Fueyo J. Delta-24-RGD modulates autophagy in glioma cells by activation of the Beclin1/PI3KC complexes. Neuro-Oncology (16th Annual Scientific Meeting of the Society for Neuro-Oncology & AANS/CNS Section on Tumors, November 17-20, 2011, Orange County, CA) 13:iii70, 2011. e-Pub 2011.
205. Hossain MB, Gururaj AE, Cortes-Santiago N, Konrad Gabrusiewicz K, Yung WKA, Fueyo J, Gomez-Manzano C. New routes for Tie2: a journey to the center of the cell. Neuro-Oncology (16th Annual Scientific Meeting of the Society for Neuro-Oncology & AANS/CNS Section on Tumors, November 17-20, 2011, Orange County, CA) 13:iii8, 2011. e-Pub 2011.
206. Alonso MM, Manterola L, Urquiza L, Cortes-Santiago N, Diez-Valle R, Tejada-Solis S, Garcia-Foncillas J, Fueyo J, Gomez-Manzano C. Sox2 and the miRNA regulation of the invasive phenotype of malignant gliomas. Neuro-Oncology (16th Annual Scientific Meeting of the Society for Neuro-Oncology & AANS/CNS Section on Tumors, November 17-20, 2011, Orange County, CA) 13:iii150, 2011. e-Pub 2011.
207. Jiang H, White E, Rios-Vicil CI, Yung WKA, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus Delta-24-RGD induces cell lysis through autophagy and autophagy-triggered caspcase activation. Neuro-Oncology (16th Annual Scientific Meeting of the Society for Neuro-Oncology & AANS/CNS Section on Tumors, November 17-20, 2011, Orange County, CA) 13:iii116, 2011. e-Pub 2011.
208. Fueyo J, Gomez-Manzano C, Conrad C, Lang F. Successful Translation of Delta-24-RGD: from the Bench to the Bedside. The 6th Conference on Oncolytic Viruses as Cancer Therapeutics. March 16-19, 2011, Las Vegas, NV, 2011. e-Pub 2011.
209. Alonso MM, Diez-Valle R, Manterola L, Cortes N, Rubio A, Garcia-Foncillas J, Fueyo J, Gomez-Manzano. Sox2 in glioblastoma multiforme. Stem Cells, Cancer and Metastasis. Keystone Symposia, Keystone, CO, March 6-11, 2011, 2011. e-Pub 2011.
210. Alonso MM, Manterola L, Diez-Valle R, Cortes-Santiago N, Liu D, Rubio A, Gacria-Foncilla J, Idoate MA, Fueyo J, Gomez-Manzano C. The multitasking of Sox2: maintaining the stemness and inducing the malignant phenotype of gliomas. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL: AACR, 2011. e-Pub 2011.
211. Urquiza L, Zalacain M, Marrodan L, Odero MD, Lecanda F, Gomez-Manzano C, Fueyo J, Sierrasesumaga L, Patino-Garcia A, Alonso MM. Enhancing autophagy as a novel approach to target osteosarcoma: combination of oncolytic adenovirus and chemotherapy. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL: AACR, 2011. e-Pub 2011.
212. Piya S, White EJ, Jiang H, Klein S, McDonnell TJ, Yung WKA, Gomez-Manzano C, Fueyo J. The oncoprotein E1B19K is part of the Beclin 1 interactome in adenovirus-infected cells. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL: AACR, 2011. e-Pub 2011.
213. Klein SR, Piya S, White EJ, Jiang H, Yung WKA, Gomez-Manzano C, Fueyo J. JNK1-phosphorylation of Bcl-2 is essential for adenoviral-induced autophagic cell death in glioma cells. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL: AACR, 2011. e-Pub 2011.
214. Alonso MM, Gomez-Manzano C, Cortes-Santiago N, Roche FR, Fueyo J. Salnomycin overcomes the chemoresistance of brain tumor stem cells. Neuro-Oncology (Annual Meeting of the Society of Neuro-Oncology, 2010, Montreal, Canada):iv96, 2010. e-Pub 2010.
215. Jiang H, Martin V, Gomez-Manzano C, Johnson DG, Alonso M, White EJ, Xu J, McDonnell TJ, Shinojima N, Fueyo J. RB/E2F1 in the crossroad of autophagy and apoptosis. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR, 2010. e-Pub 2010.
216. Jiang H, Martin V, Gomez-Manzano C, Johnson DG, Alonso M, White EJ, Xu J, McDonnelll T, Shinojima N, Fueyo J. Rb:E2F: Gatekeepers of autophagy and apoptosis in glioma cells. Neuro-Oncology (Annual Meeting of the Society of Neuro-Oncology, 2010, Montreal, Canada):iv22, 2010. e-Pub 2010.
217. Alonso M, Gomez-Manzano C, Vaillant B, Xu J, Liu D, Jiang H, White EJ, Colman H, Fueyo J. Salinomycin displays more potent anticancer effect against brain tumor stem cells than temozolomide. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR, 2010. e-Pub 2010.
218. Alonso M, Gomez-Manzano C, Vaillant B, Xu J, Liu D, Jiang H, White EJ, Colman H, Fueyo J. Salinomycin displays more potent anticancer effect against brain tumor stem cells than temozolomide. AACR Special Conference, Genetics and Biology of Brain Cancers, San Diego, CA, 2009. e-Pub 2009.
219. Whire E, Jiang H, Gomez-Manzano C, Fueyo J. Adenovirus-induced autophagy requires expression of stress-related kinases but no dowregulation of akt. Neuro-Oncology (2009 Joint Meeting of SNO and AANS/CNS Section on Tumors, Oct 22-24, 2009, New Orleans, LA) 11(5):573, 2009. e-Pub 2009.
220. Alonso MM, liu D, Xu J, Pabbissety SK, Colman H, Yung WKA, Fueyo J, Gomez-Manzano C. Sox2 plays a pivotal role in the self-renewal property of brain tumor stem cells. Neuro-Oncology (2009 Joint Meeting of SNO and AANS/CNS Section on Tumors, Oct 22-24, 2009, New Orleans, LA) 11(5):679, 2009. e-Pub 2009.
221. White E, Jiang H, Xu J, Gomez-Manzano C, Fueyo J. Involvement of autophagy in oncolysis: E1A is required but not sufficient. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR, 2009. e-Pub 2009.
222. Alonso MM, Pabbisetty SK, Liu D, Xu J, Balasubramaniyan V, Colman H, Fueyo J, Gomez-Manzano C. Sox2 is the engine of the self-renewal machinery in brain tumor stem cells. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR, 2009. e-Pub 2009.
223. Jiang H, White E, Guma S, Ji Y, Gomez-Manzano C, Conrad CA, Fueyo J. Enhanced oncolysis of glioma cells by Delta-24-RGD combining with 2-deoxyglucose through autophagic cell death. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR, 2009. e-Pub 2009.
224. Liu D, Martin V, Xu J, Fueyo J, Gomez-Manzano C. Role of tie2 signaling in adhesion and the invasive phenotype of gliomas. Neuro Oncol 10(5):774, 2008. e-Pub 2008.
225. Jiang H, White E, Alonso M, Xu J, Yung WKA, Gomez-Manzano C, Fueyo J. Detection of autophagy in vivo: Lessons from virotherapy of gliomas. Neuro Oncol 10(5):797, 2008. e-Pub 2008.
226. Martin V, Alonso MM, Xu J, Liu D, Fueyo J, Gomez-Manzano C. A window for therapy: Tie2 as a new accomplice in the multidrug resistance phenotype of gliomas. Neuro Oncol 10(5):796, 2008. e-Pub 2008.
227. Martin V, Alonso MM, Xu J, Liu D, Colman H, Yung WKA, Fueyo J, Gomez-Manzano C. Unmasking the face behind recurrence: mechanisms underlying drug resistance of brain tumor stem cells. J Neurology (18th Meeting of the European Neurological Society (ENS), Nice, France), 2008. e-Pub 2008.
228. Liu D, Martin V, Xu J, Fueyo J, Gomez-Manzano C. Tie2 signaling mediates adhesion to the endothelial compartment in cancer. 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA, 2008. e-Pub 2008.
229. Martin V, Xu J, Alonso M, Liu D, Fueyo J, Gomez-Manzano C. Tie2 upregulates ABC transporters and promotes drug resistance. 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA, 2008. e-Pub 2008.
230. Jiang H, Xu J, Lang F, Colman H, Gomez-Manzano C, Bogler O, Latha K, Yung WKA, Fueyo J. Delta-24-RGD induces autophagy in brain tumor stem cells and prolongs survival in glioma-bearing mice. 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA, 2008. e-Pub 2008.
231. White E, Jiang H, Alonso M, Piao Y, Xu J, Conrad C, Yung WKA, Gomez-Manzano C, Fueyo J. Atg5 is required for adenovirus-induced autophagy in cancer cells. 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA, 2008. e-Pub 2008.
232. Alonso M, Gomez-Manzano C, Jiang H, Martin V, Liu D, Xu J, Yung WKA, Gilbert M, Fueyo J. Role of the silencing of the MGMT promoter in the therapeutic synergy between Delta-24-RGD and temozolomide. 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA, 2008. e-Pub 2008.
233. Alonso M, Gomez-Manzano C, Jiang H, Xu J, Piao Y, Yokoyama T, Kondo S, Yung WKA, Fueyo J. Delta-24–RGD in combination with RAD001 induces autophagic cell death and 80% long-term survivors. Neuro Oncol 9(4):491, 2007. e-Pub 2007.
234. Martin V, Liu D, Xu J, Fueyo J, Gomez-Manzano C. Tie2 mediates adhesion-dependent cell survival in gliomas. Neuro Oncol 9(4):471, 2007. e-Pub 2007.
235. Lee OK, Fueyo J, Xu J, Alonso MM, Colman H, Gomez-Manzano C. Tie2 links brain tumor stem cells to vascular structures in human glioblastoma. Keystone Symposia on Stem Cell Interactions with their Microenvrionmental Niche, 2007. e-Pub 2007.
236. Lee OK, Fueyo J, Xu J, Fuller GN, Aldape K, Colman H, Gumin J, Lang FF, Yung WKA, Gomez-Manzano C. Glial tie2 is co-expressed with stem cell-like markers and mediates adhesion of neoplastic astrocytes to tumoral vascular structures. Neuro-oncol 8(4):392, 2006. e-Pub 2006.
237. Lee OH, Fueyo J, Xu J, Gumin J, Popoff S, Lang F, Aldape K, Yung WKA, Colman H, Gomez-Manzano C. Tie2 bridges brain tumor stems cells with vascular structures within a putative stem cell niche. 59th Annual Symposium on Cancer Research, 2006. e-Pub 2006.
238. Lee OH, Xu J, Jiang H, Alonso MM, Piao Y, Olson MV, Medrano DR, Full GN, Yung WKA, Fueyo J, Gomez-Manzano C. Expression of Tie2 receptor is associated with adhesion properties of glioma cell and malignancy of glioma tumors. 10th Annual Trainee Recognition Day and Research Exposition, The University of Texas M. D. Anderson Cancer Center, 2006. e-Pub 2006.
239. Gomez-Manzano C, Holash J, Xu J, Lee OH, Fueyo J, Rudge J, Bekele BH, Aldape K, Yung WKA. The soluble decoy receptor for VEGF, VEFG Trap, induces antiglioma effect in vivo. Neuro-Oncol 7(3):354, 2005. e-Pub 2005.
240. Alonso M, Alemany R, Gomez-Manzano C, Yung WKA, Jiang H, Fueyo J. ICOVIRr-2, an old friend with a new face: E2F-1 mediated glioma selectivity for Delta24-RGD. Neuro-Oncol 7(3):377, 2005. e-Pub 2005.
241. Olson M, Medrano D, Jiang H, Gomez-Manzano C, Alonso M, Aldape K, Price R, Yung WKA, Fueyo J. Developmental abnormalities and oncogenesis in the brain of a transgenic E2F1 mouse model. Neuro-Oncol 7(3):289, 2005. e-Pub 2005.
242. Alonso M, Alemany R, Gomez-Manzano C, Yung WKA, Jiang H, Fueyo J. Oncolytic adenovirus Icovir-2 shows improved therapeutic index than D24-RGD for glioma. 96th annual meeting AACR, Anaheim, CA, April 16-20, 2005. e-Pub 2005.
243. Olson MV, Medrano DR, Alonso MM, Johnson D, Price R, Yung WKA, Gomez-Manzano C, Fueyo J. Developmental abnormalities and oncogenesis in the brain of a transgenic E2F1 mouse model. 8th Cancer Research UK Beatson International Cancer Conference, Glasgow, UK, July 19-22, 2005. e-Pub 2005.
244. Olson MV, Alonso M, Medrano D, Sheng X, Gomez-Manzano C, Jiang H, Yung WKA, Fueyo J. E2F1 transcriptionally activates PTEN. 96th Annual Meeting AACR, Anaheim, CA, April 16-20, 2005. e-Pub 2005.
245. Olson M, Jiang H, Medrano D, Gomez-Manzano C, Aldape K, Fueyo J. GFAP-E2F1 transgenic mouse provides the first evidence of an oncogenic role of E2F1 in brain tumor formation. Keystone Conferences: Cellular Senescence and Cell Death, Keystone, Colorado, March 3 – 9, 2005. e-Pub 2005.
246. Jiang H, Medrano D, Gomez-Manzano C, LeMoine M, Alemany R, Olson M, Alonso M, Conrad C, Yung WKA, Fueyo J. Downmodulation of E1A protein expression as a novel strategy to design cancer selective adenoviruses. 96th annual meeting AACR, Anaheim, CA, April 16-20, 2005. e-Pub 2005.
247. Gomez-Manzano C, Holash J, Xu J, Lee OH, Fueyo J, Rudge J, Bekele BH, Aldape K, Yung WKA. Treatment of glioma-bearing mice with VEGF Trap results in significant prolongation of survival. 96th annual meeting AACR, Anaheim, CA, April 16-20, 2005. e-Pub 2005.
248. Alonso M, Yung WKA, Fueyo J, Gomez-Manzano C. E2F1 and telomerase expression in glioblastomas: mechanistic linkage and prognostic significance. 8th Cancer Research UK Beatson International Cancer Conference, Glasgow, UK, July 19-22, 2005. e-Pub 2005.
249. Jiang H, Alemany R, Gomez-Manzano C, Yung WKA, Sawaya R, Lang F, Fueyo J. Comparison of the antiglioma effect of E1A and E1B-55kD-mutant oncolytic adenoviruses. AANS/CNS Section on tumors Sixth Biennial Satellite Symposium, San Francisco, CA. October 21-22, 2004. e-Pub 2004.
250. Medrano D, Jiang H, Gomez-Manzano C, Olson M, Lemoine M, Yung WKA, Fueyo J. Replication-competent adenoviruses with impaired p300/CBP binding express low E1A protein levels: implications for oncolytic therapy. 8th Annual Trainee Recognition Day and Research Exposition. The University of Texas M. D. Anderson Cancer Center, Houston, TX; May 14, 2004. e-Pub 2004.
251. Jiang H, Gomez-Manzano C, Medrano D, Cass A, Alonso M, Alemany R, Yung WKA. The level of E1A as a factor for tumor selectivity in oncolytic adenoviruses. 95th Annual Meeting of American Association for Cancer Research, Orlando, FL, March 27-31, 2004. e-Pub 2004.
252. Gomez-Manzano C, Xu J, Fueyo J, Aldape K, Bekele NB, Lemoine M, Fuller G, Yung WKA. Significant correlation of Angiopoietin-2 and Nestin expression in human glioblastomas. 95th Annual Meeting of American Association for Cancer Research, Orlando, FL, March 27-31, 2004. e-Pub 2004.
253. Alonso MM, Gomez-Manzano C, Aldape K, Jiang H, Xu J, Kondo Y, Fueyo J. E2F1 upregulates telomerase: cell-cycle related telomerase activity in sarcoma cells. 95th Annual Meeting of American Association for Cancer Research, Orlando, FL, March 27-31, 2004. e-Pub 2004.
254. Medrano D, Jiang H, Johnson D, Aldape K, Olson M, Gomez-Manzano C, Fueyo J. Transgenic overexpression of E2F1 in the brain in E2F4 null background results in severe hydrocephalus similar to E2F5 null mice. Special AACR Conference on Cell Cycle and Cancer: Pathways and Therapies; Fort Lauderdale, FL, Dec 1–5, 2004. e-Pub 2004.
255. Conrad CC, Ji Y, Gumin J, Lang FF, Sawaya R, Yung WKA, Gomez-Manzano C, Fueyo J. Direct comparison of the antiglioma effects of Delta-24-hyCD and Ad-hyCD. Neuro-Oncol 5:298-299, 2003. e-Pub 2003.
256. Alonso MM, Aldape K, Gomez-Manzano C, Kondo Y, Fueyo J. Is E2F1 driven force behind telomerase activity in glioblastomas?. 10th Annual Poster Neuroscience Session, University of Texas, Houston. Dec 6, 2003. e-Pub 2003.
257. Fueyo J, Gomez-Manzano C, Yung WKA, Sawaya R, Lang FF. Dose dependence antiglioma effect of Delta-24-RGD in the intracranial U-87 MG animal model. Neuro-Oncol 5:300-301, 2003. e-Pub 2003.
258. Gomez-Manzano C, Jiang H, Stolarek R, Lang FF, Yung WKA, Fuller GN, Fueyo J. U-87 MG Animal Model: predictability of growth kinetics and its use in oncolytic therapy for gliomas. Special AACR meeting, Orlando, FL, Febr 19-23, 2003. e-Pub 2003.
259. Alonso M, Aldape K, Gomez-Manzano C, Kondo Y, Fueyo J. Is E2F1 driven force behind telomerase activity in glioblastomas?. Neuro-Oncol 5:288, 2003. e-Pub 2003.
260. O-K L, Xu J, Fueyo J, Lang FF, Yung WKA, Gomez-Manzano C. The blood vessel-destabilizer tool: Angiopoietin-2 as antiglioma treatment. 10th Annual Poster Neuroscience Session, University of Texas, Houston. Dec 6, 2003. e-Pub 2003.
261. Jiang H, Medrano D, Gomez-Manzano C, Courmier F, Yung WKA, Fueyo J. Replication competent adenoviruses with impaired p300/CBP binding express low E1A proteins levels: implication for oncolytic therapy. Neuro-Oncol 5:301-302, 2003. e-Pub 2003.
262. Gomez-Manzano C, Fueyo J, Xu J, H-J L, Courmier FW, Hu CH, Liu TJ, Yung WKA. Angiopoietin-2 downmodulates VEGF-A: Balancing act in gliomas. Neuro-Oncol 5:282-283, 2003. e-Pub 2003.
263. Gomez-Manzano C, Aldape KD, Fueyo J, Xu J, Stolarek R, Hu CH, Lang FF, Yung WKA. The blood vessel-destabilizer tool: Angiopoietin-2 as antiglioma treatment. Neuro-Oncol 5(4):283, 2003. e-Pub 2003.
264. Fueyo J, Gomez-Manzano C, Jiang H, Lemoine M, Stolarek R, Courmier F, Jasti S, Conrad C, Yung WKA. Oncolytic adenoviruses, CPT-11, and topoisomerase I: Mechanisms underlying chemosensitization. Neuro-Oncol 4:322, 2002. e-Pub 2002.
265. Gomez-Manzano C, Fueyo J, Lemoine M, Yung WKA, Fuller G. Neoangiogenesis development in the intracranial U-87 MG animal model. Neuro-Oncol 4:308, 2002. e-Pub 2002.
266. Fueyo J, Gomez-Manzano C, Alemany R, Lemoine M, Stolarek R, Jasti S, Courmier F, Jiang H, Lamfers M, Dirven C, Curiel D, Yung WKA. Oncolytic adenovirus for glioma therapy. Neuro-Oncol 4:S35, 2002. e-Pub 2002.
267. Fueyo J, Gomez-Manzano C, Lemoine MG, He J, Khan A, Conrad C, Yung WK, Lang FF. Characterization of the anti-glioma effect of a second-generation conditionally replicating adenovirus unable to bind Rb and p53. Neuro-Oncol 3(4):290, 2001. e-Pub 2001.
268. Gomez-Manzano C, Hu M, Glass T, Fueyo J, Yung WKA. Regulation of VEGF expression in gliomas: evidence of the involvement of different pathways in different human glioma cells. Neuro-oncol 3(4):268, 2001. e-Pub 2001.
269. Fueyo J, Gomez-Manzano C, Fuller FN, et al. Treatment of gliomas xenografts with D24 oncolytic adenovirus: a pathological study. Neurology 8 Suppl. 3:A407, 2001. e-Pub 2001.
270. Fueyo J, Lemoine MG, Gomez-Manzano C, Rao S, Lang FF, Conrad C, Groves M, Yung WK. Chemotherapy enhancement of the antiglioma effect of the Delta-24 adenovirus. Neuro-Oncol 3:289-290, 2001. e-Pub 2001.
271. Gomez-Manzano C, Fueyo J, Glass T, Hu M, Lee HY, He J, Mitlianga P, Lemoine M, Liu TJ, Yung WKA. Treatment with MMAC/PTEN modifies the antiangiogenic phenotype of glioma cells. Proc Am Soc Clin Oncol 20:261a, 2001. e-Pub 2001.
272. Gomez-Manzano C, Fueyo J, Glass T, Hu M, Y-H L, Mitlianga M, Yung WKA. Evidence of MMAC/PTEN-mediated modulation of the angiogenesis phenotype of glioma cells. Neurology 56 Suppl 3:A407, 2001. e-Pub 2001.
273. Conrad CA, Gomez-Manzano C, Fuller GN, Lemoine M, Khan A, Lang FF, T-J L, Yung WKA, Fueyo J. Genome modifications and chemotherapy enhancement of D24 antiglioma effect. Neurology 56 Suppl. 3:A407-8, 2001. e-Pub 2001.
274. Groves MD, Lemoine M, Gomez-Manzano C, Mitlianga P, Yung WKA, Fueyo J. E2F-1 increases the chemosensitivity of human glioma cells to temozolomide and BCNU. Neurology 56:A480, 2001. e-Pub 2001.
275. Gomez-Manzano C, Mitlianga P, Koul D, Y-H L, McDonnell TJ, Glass T, Liu TJ, Fueyo J, Yung WKA. E2F transcriptionally upregulates Bcl-2. Neuro-Oncol 2(4):265, 2000. e-Pub 2000.
276. Gomez-Manzano C, Fueyo J, Glass T, Koul D, Y-H L, Y-X S, Liu TJ, Yung WKA. MMAC/PTEN downregulates VEGF in gliomas. Neuro-Oncol 2(4):265, 2000. e-Pub 2000.
277. Fueyo J, Gomez-Manzano C, Alemany R, Yung WKA, Kyritsis AP. Redirecting adenoviruses to glioma: RGD-D24 infects glioma cells by adenovirus receptor-independent system. Neurology 54, Suppl. 3:A35-A35, 2000. e-Pub 2000.
278. Mitlianga P, Gomez-Manzano C, Lemoine M, Hu M, Liu TJ, Levin VA, Yung WKA, Kyritsis AP, Fueyo J. E2F-2 enhances p53 anti-glioma effect. Neuro-Oncol 2(4):278, 2000. e-Pub 2000.
279. Lemoine M, Groves MD, Gomez-Manzano C, Mitlianga P, Levin VA, Kyritsis AP, Yung WKA Fueyo J. E2F enhances temozolomide and BCNU anti-glioma effect. J Neurol 247, Suppl. 3, 2000. e-Pub 2000.
280. Gomez-Manzano C, Mitlianga P, Fueyo J, Liu TJ, Kyritsis AP, Yung WKA. Transfer of E2F-1 results in upregulation of bcl-2, p21 and p27: action-reaction. Proc Am Assoc Cancer Res 41:351, 2000. e-Pub 2000.
281. Gomez-Manzano C, Mitlianga P, Fueyo J, Liu TJ, Kyritsis AP, Yung WKA. Paradoxical upregulation of Bcl-2, p21 and p27 in glioma cells in route to E2F-1-mediated apoptosis. Neurology 54, Suppl. 3, 2000. e-Pub 2000.
282. Gomez-Manzano C, Fueyo J, Alemany R, Mitlianga P, Kyritsis AP, Yung WKA. Increased anti-glioma effect by adenovirus containing modification in the fiber proteins. J Neurol 247, Suppl. 3, 2000. e-Pub 2000.
283. Fueyo J, Khan A, Gomez-Manzano C, Shono T, Lemoine M, Alemany R, Curiel DT, Y-X S, Liu TJ, Levin VA, Yung WKA, Lang FF. Treatment of intracranial gliomas with D24-RGD. Neuro-Oncol 2(4):263, 2000. e-Pub 2000.
284. Fueyo J, Khan A, Gomez-Manzano C, et al. Treatment of intracranial gliomas with D24 adenovirus. J Neurol 247, Suppl. 3(III):61, 2000. e-Pub 2000.
285. Fueyo J, Gomez-Manzano C, Alemany R, et al. Insertion of an RGD motif enhances the oncolytic effect of the D-24 adenovirus. Proc Am Assoc Cancer Res 41:352, 2000. e-Pub 2000.
286. Fueyo J, Gomez-Manzano C, Lemoine M, Mitlianga P, Yung WKA, Kyritsis AP. Induction of S phase by E2F-1, E2F-2, and E2F-4 enhances the effect of temozolomide on glioma viability. J Neurol 247 Suppl. 3(III):61, 2000. e-Pub 2000.
287. Fueyo J, Gomez-Manzano C, Mitlianga P, Lee PSY, Yung WKA, Kyritsis AP. Delta-24 oncolytic adenovirus has antiglioma effect in vivo. Neuro-Oncol 1:311, 1999. e-Pub 1999.
288. Fueyo J, Gomez-Manzano C, Alemany R, et al. Targeting the E2F pathway with tumor-selective adenovirus. Neurology 52, Suppl. 2:A474-A474, 1999. e-Pub 1999.
289. Fueyo J, Gomez-Manzano C. Control molecular del ciclo celular y la apoptosis: nuevos tratamientos para los gliomas. Neurologia 13(7):349-55, 1998. e-Pub 1998. PMID: 9810797.
290. Kyritsis AP, Fueyo J, Gomez-Manzano C, Lee PSY, Alemany R, Martin-Duque P, Levin VA, Yung WKA. A bicistronic recombinant adenovirus carrying both p53 and p16 tumor suppressor genes for treatment of p53 resistant gliomas. Neurology 50 Supp 4:A272, 1998. e-Pub 1998.
291. Im SA, Gomez-Manzano C, Fueyo J, Liu TJ, Ke LD, Lee PSY, H-Y L, Kim JS, Kyritsis AP, Yung WKA. Adenovirally-mediated transfer of antisense-VEGF cDNA inhibits glioma growth in vivo. J Neurol 245:461, 1998. e-Pub 1998.
292. Im SA, Gomez-Manzano C, Fueyo J, Liu TJ, Ke LD, Lee PSY, H-Y L, Kim JS, Kyritsis AP, Yung WKA. Adenovirally-mediated antisense-VEGF downregulated the VEGF expression in glioma. Proc Am Assoc Cancer Res 39, 1998. e-Pub 1998.
293. Gomez-Manzano C, Fueyo J, Yung WKA, Majumder S, Levin VA, Kyritsis AP. Transcriptional activation is not necessary for E2F-1-mediated suppression of glioma growth. J Neurol 145:487, 1998. e-Pub 1998.
294. Gomez-Manzano C, Fueyo J, Kyritsis AP, Liu TJ, McDonnell TJ, Levin VA, Yung WKA. The cutting edge of apoptosis: direct and effective anti-cancer action of E2F-1 in glioma cells resistant to p53-mediated apoptosis. J Neurol 50 Supp 4:A271, 1998. e-Pub 1998.
295. Gomez-Manzano C, Fueyo J, Kyritsis AP, Liu TJ, Alemany R, Martin Duque P, Levin VA, Yung WKA. Synergistic effect of p53, p53-p16 and E2F-1 in gliomas suggests different mechanism of activation of apoptosis. Proc Am Assoc Cancer Res 39:138, 1998. e-Pub 1998.
296. Fueyo J, Gomez-Manzano C, Lee PSY, et al. A novel tumor specific replication restricted adenoviral vector for glioma therapy. J Neurol 245:461, 1998. e-Pub 1998.
297. Fueyo J, Gomez-Manzano C, Yung WKA, Martin-Duque P, Levin VA, Kyritsis AP. E2F-dependent glioma apoptosis in the absence of transcriptional activation of E2F-target genes. Proc Am Assoc Cancer Res 39:138, 1998. e-Pub 1998.
298. Fueyo J, Gomez-Manzano C, Alemany R, et al. A single adenoviral vector able to transfer p53 and p16 for treatment of p53-resistant gliomas. J Neurol 245:460, 1988. e-Pub 1988.
299. Gillard A, Shin DH, Garcia Moure M, Parthasarathy A, Lopez-Rivas A, Jiang H, He J, Frost M, Fan X, Alemany R, Lang FF, Alonso M, Fueyo J, Gomez-Manzano C. The Underpinning Mechanisms of Innate Immunity in Glioma Viroimmunotherapy. AdenoNet 2025.
300. Gomez-Manzano C, Alonso M, Alemany R, Fueyo J. Unmasking the Hidden Challenge: The Core Dilemma of Cancer ViroImmunotherapy. AdenoNet 2025.
301. Parthasarathy A, Frost M, He J, Gillard A, Shin DH, Lopez-Rivas A, Fan X, Jiang H, Angelis, Solbes C, Venneti S, Phoenix T, Alonso M, Gomez-Manzano C, Fueyo J. Pharmacological inhibition of P300 boosts immune infiltration induced by Delta-24-RGD in H3K27-altered Diffuse Midline Glioma. 22nd International Symposium on Pediatric Neuro-Oncology (ISPNO 2026).

Book Chapters

1. Martinez-Velez N, Gomez-Manzano C, Fueyo J, Patiño-Garcia A, Alonso MM. Oncolytic Virotherapy for Gliomas: A Preclinical and Clinical Summary. In: Gene Therapy in Neurological Disorders. 1st edition. Academic Press (Elsevier), 357-384, 2018.
2. Xipell E, Rivera-Molina Y, Gomez-Manzano C, Jiang H, Alonso MM, Alemany R, Fueyo J. Conditionally replicative adenoviruses-Clinical trials. In: Adenoviral Vectors for Gene Therapy. 2nd. Elsevier, Academic Press, 335-348, 2016.
3. Balvers RK, Gomez-Manzano C, Jiang H, Piya S, Klein SR, Lamfers MLM, Dirven CMF, Fueyo J. Advances in Oncolytic Virotherapy for Brain Tumors. In: Gene Therapy of Cancer. 3rd. Elsevier, 137-151, 2014.
4. Alonso MM, Jiang H, Gomez-Manzano C, Fueyo J. Targeting Brain Tumor Stem Cells with Oncolytic Adenoviruses. In: Methods Mol Biol. Humana Press, 111-25, 2012.
5. Gomez-Manzano C, Jiang H, Alonso M, Yung WK, Fueyo J. Gene Therapy. In: Handb Clin Neurol. 3rd. Elsevier, 331-8, 2012.
6. Alonso M, Fueyo J, Gomez-Manzano C. Malignant Gliomas: Role of E2F1 Transcription Factor. In: Methods of Cancer Diagnosis, Therapy, and Prognosis. Springer, 89-97, 2011.
7. Alonso MM, Fueyo J, Johnson DG, Gomez-Manzano C. The oncogenic role of E2F1 in brain tumors. In: Control of Cellular Physiology by E2F Transcription Factors. Research Signpost, 257-270, 2008.
8. Alonso MM, Gomez-Manzano C, Alemany R, Jiang H, McCormick F, Fueyo J. Conditionally replicative adenoviruses as antitumoral agents: Past, present and future. In: Cancer and Gene Therapy. Transworld Research Network, 41-54, 2007.
9. Jiang H, McCormick F, Gomez-Manzano C, Curiel DT, Lang FF, Yung WKA, Fueyo J. Replicating viruses for brain tumor treatment. In: Gene Therapy for Neurological Disorders. Taylor and Francis Group, 293-326, 2006.
10. Fueyo J, Gomez-Manzano C, McDonnell TJ. Regulation of Cell-Cycle and Apoptosis in Human Brain Tumors. In: Brain Tumors. In series: Contemporary Cancer Research. Part II. Humana Press Inc, 249-264, 2005.
11. Stolarek R, Fueyo J, Gomez-Manzano C, Jiang H, Yung WKA. Gene Therapy for Gliomas: Targeting the Cancer Genome. In: Genomic and Molecular Neuro-Oncology. In series: Molecular Oncology and Cancer Genomics. Jones and Bartlett Publishers Inc, 281-302, 2003.
12. Gomez-Manzano C, Fueyo J, Yung WKA. Gene therapy approaches for gliomas. In: Brain Cancer. In series: American Cancer Society Atlas. BC Decker Inc Publisher, 219-237, 2001.
13. Gomez-Manzano C, Fueyo J, Kyritsis AP, Yung WKA. Tumor suppressor gene therapy for brain tumors. In: Gene Transfer and Therapy for Neurological Disorders & Brain Tumors. Humana Press Inc, 225-239, 1998.

Letters to the Editor

1. Fueyo J, Gomez-Manzano C, Pascual J, Pou A. Paraneoplastic syndromes. Neurology 43: 236, 1993.
2. Gomez Manzano C, Fueyo J, Pedro-Botet Montoya J, Fernandez-Sola J. Bezafibrate-induced necrotizing myopathy. Med Clin (Barc) 96: 439, 1991.
3. Gomez-Manzano C, Fueyo J, Miralles R, Gutierrez J. Wernicke's encephalopathy in a female patient with the acquired immunodeficiency syndrome. Med Clin (Barc) 95: 754-5, 1990.
4. Gomez Manzano C, Fueyo J, Garces JM, Gutierrez J. Internuclear ophthalmoplegia related to opiate overdose. Med Clin (Barc) 94: 637, 1990.